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ABBREVIATIONS 
PRRT    Peptide Receptor Radionuclide Therapy  
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AE   Auger electrons 
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λ                            Decay constant 
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c.a   carrier added  
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CPS   Counts per Second 
ROI   Region of Interest 
RNP   Radionuclide Purity 
CT    Computed Tomography 
SPECT   Single Photon Emission Computed Tomographic images 
AUC   Area under the curve 
3D   Three dimensional 
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ABSTRACT 
The use of radio-labeled somatostatin analogs, such as 177Lu-labelled DOTATATE, in PRRT, has 
based on the studies performed until now, shown to be promising for RNT disseminated 
neuroendocrine tumors [1].  In this regard, the aim of treatment is to assure the delivery of the 
highest possible absorbed dose to the tumor cells, while saving the normal tissues [1],  
meaning, to achieve a higher activity uptake in tumors with neuroendocrine origin while 
assuring the lowest possible radio-toxicity in normal organs [2]. 
The key challenge associated with the absorbed dose distribution in the body upon 
administration of PRRT using 177Lu-DOTATATE is the absorbed dose to the kidneys, as being the 
dose limiting organs in PRRT [7]. The main excretion route of 177Lu-DOTATATE is through urine, 
where >65% of the total administered activity is excreted. This has lead us to investigate the 
long time retention of 177Lu in the total body, and also to estimate the absorbed dose given by 
possible radionuclide impurities.  
According to the declaration from the producer, a sample of 177Lu contains less than 0.05% 
of 177mLu. In order to investigate whether the 177mLu contribution to the absorbed dose is as low 
that it can be tolerated or even neglected, spectroscopy measurements have been performed 
on patients receiving therapy with 177Lu-DOTATATE at Skåne University Hospital [15]. Prior to 
performing these measurements, the spectroscopy equipment has been carefully calibrated. 
The data obtained from patient measurements have been analyzed using different methods, 
and have been combined with imaging based data, obtained as part of the routine dosimetry 
performed at Skåne University Hospital.  
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INTRODUCTION 
In radionuclide therapy (RNT), a radioactively labeled pharmaceutical is used for patient 
treatment. The underlying idea of RNT is that the pharmaceutical is designed to accumulate in 
the target tissue, e.g. the tumor. The radioactive label is thus carried to the tumor, and at decay 
by particle emission an absorbed dose is delivered for the internal radiation treatment.  
The administered therapy activity of 177Lu-Dotatate is excreted through urine, and a concern is 
therefore the retention of 177Lu activity in the kidneys, with possible renal damage as side effect 
of the treatment.  
Currently, a clinical patient trial is being performed at the clinic of Oncology, Skåne University 
Hospital, where patients with disseminated neuroendocrine tumors are being treated 
with 177Lu-[DOTA0,Tyr3] Octreotate (also termed 177Lu-DOTATATE). The radionuclide 177Lu 
disintegrates by beta-decay and emits electrons that are used for induction of the absorbed 
dose. 177Lu also has gamma-emissions, allowing for external measurement of the 
radiopharmaceutical distribution, using a gamma camera. By imaging at several times after 
injection, the radiopharmaceutical distribution over time is measured.  
Production of 177Lu can be performed in two ways, both involving neutron activation. One of 
the production paths also produces a small amount of metastable 177mLu. Owing to the small 
amount of 177mLu, the absorbed dose induced by 177mLu is normally not considered in the 
calculation of the absorbed dose. However, considering the physical half-lives of 177Lu 
and 177mLu, which are 6.7 and 160.4 days respectively, there may be a non-negligible 
contribution from 177mLu.  
In the standard procedures for patient dosimetry, the long-term retention of 177Lu /177mLu -
DOTATATE is not measured. Instead, it is extrapolated from imaging measurements performed 
during the first week after administration.  
The aim of this study is to investigate some of the research questions coupled with renal 
dosimetry of patients treated with 177Lu-DOTATATE. 
 6 | P a g e  
 
The specific aim is to investigate the long-term retention of 177Lu /177mLu -DOTATATE, by using 
gamma spectrometry measurements during the first or second months after administration, as 
a complement to routine imaging-based studies. Furthermore, the project aims to make 
dosimetric conclusions based on these new long-term data.  
For this purpose, a method for the estimation of the activity at different time points and 
determination of the absorbed doses has been developed.   
A methodology for the estimation of TB Activity has been established using NaI(TI) and HPGe 
detector systems. A well defined calibration geometry for measurement of reference sources 
of 57Co and 137Cs has been established because these radionuclides emits gamma energies close 
to the gammas of 177Lu at 208 keV and 177mLu at 378 keV, 418 keV, respectively. Careful 
measurement of the background and subsequent subtraction has been also performed. 
Spectral data analysis was performed both automatically, using the Maestro spectrometry 
software, and manually using Excel, values of the number of counts versus the channel number. 
Here, the detector efficiency and the energy resolution were determined.  
A brief introduction to PPRT and the detector systems will be described. The production routes 
of 177Lu and its decay scheme as well as the decay scheme of 177mLu will also be presented. As 
the aim of the study is associated with the activity determination of 177Lu at different time 
points and the contribution of 177mLu (based on the decay scheme), a detailed observation on 
the outcomes will be presented. The results obtained will be further discussed under the 
chapter Results and a comparison on the Activity determination outcomes using the internal 
radiation dosimetry will also be addressed. 
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I. Radiation Therapy/Peptide Receptor Radionuclide Therapy  
The use of radio-labeled somatostatin analogs in PRRT, has shown to be promising for the RNT 
treatment of neuroendocrine tumors [1].  The main challenge associated with this kind of 
treatment is to assure the delivery of the highest activity in the tumor cells, while saving the 
normal tissues [1]. The aim is to achieve a higher uptake from tumors with neuroendocrine 
origin while assuring a lowest possible radio-toxicity in normal organs [2]. The 177Lu-DOTATATE 
has shown a high level of absorption in tumor tissue with a very high affinity [3]. 
In PRRT the excretion from the body is mainly done through the kidneys, leading to the concern 
that kidneys are the main organ at risk with a high retention of radioactivity considered to be a 
dose limiting organ for the PRRT use. By evaluating the absorbed dose to the kidneys, it is 
believed that renal damage from the radiation therapy can be reduced [7, 1].  
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II. Gamma – Ray Spectroscopy 
The γ-ray, an electromagnetic radiation produced by nuclear reactions, is characterized by a 
high energy and short wavelength in the electromagnetic spectrum. This high energy may cause 
damage when it is absorbed by living cells.  
The electromagnetic nature of γ-ray photons, enables a strong interaction with the charged 
electrons in the atoms of matter. Therefore, the detection of γ-rays depends on the interaction 
process of  γ-ray photons, which causes a trasnfer of all or part of the photon energy to the 
electrons, withing the absorbing material. The electrons created as a result of γ-ray interactions 
will be characterized with an equal Emax  to that of γ-ray photons. During the interaction 
process, they will loose some energy and as a result will slow down. The energy loss is as a 
result of the excited atoms and Bremstrahlung emission withing the material. Finally, as a result 
the released charge by electrons will be collected by the PMT and detector electronics, and an 
electronic pulse is generated with a height that is proportional to the deposited radiation 
energy. This thus enables identification of the gamma energy [39].  
At β- decay of a radioactive isotope, it eventually reaches the ground state of the daugter 
isotope. It may decay to excited states, which upon deexcitation causes a subsequent release of 
energy by emission of  γ-rays. The γ-ray energies can be detected and measured by employing a 
suitable detector system which is useful for γ-ray energy detection as well as the determination 
of the activity of the source [38,39].  
There are several factors associated with the impact and choice of the detector system to be 
used: particle range, energy resolution, efficiency, count rate performance and price. 
For the purpose of this study two different types of detector systems for γ-ray spectroscopy 
have been used: the standard NaI(Tl) detector system and a HPGe detector system (which has a 
high energy resolution and lower background noise). 
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            II.1 NaI(TI) Scintillation Detector System 
For this project a NaI(TI) solid state scintillation detector system has been used. The crystal is 
bounded with a reflective material to minimize the loss of scintillation light. A layer of 
Aluminum is also used for protection of the sensitive crystal and also because of the 
hygroscopic behavior of NaI (a salt). The crystal is optically coupled to a PMT. The PMT consists 
of a photocathode followed by a series of dynodes ending at the anode. In the photocathode 
through the photoelectric absorption of photons, the release of electrons is caused in the 
vacuum of the PMT [27, 38, 39]. 
The γ-rays may deposit energy when interacting with the scintillator and the pulse size from the 
detector depends on the γ-ray energy that has been deposited in the scintillator. The points of 
photon interaction within the detector crystal are homogenously distributed for higher photon 
energies. For lower energies, the interactions mostly are in the front side of the crystal volume 
[38, 39]. The interaction of γ-rays with the NaI(TI) crystal can undergo different interaction 
processes: [38, 39] 
- Photoelectric absorption – an interaction of a photon with the absorber atom, the photon 
vanishes and an energetic electron is ejected and the overall contact is made with the 
atom as a whole.  
- The Coherent Scattering - during the interaction process of the incident γ-ray photon with 
the matter, causing an excitation of the atom, which then scatters. The Compton Scattering 
characterized as a process of the interaction of incident γ-ray with an orbital electron, and 
giving  part of its energy to the orbital electron [38,39]. This process causes the ejection of 
the electron, and scattering of  γ-ray  photon (which carries radiation energy away from 
the detector material). Thus, the deposited energy in the crystal is smaller than for the 
photoelectric absorption process, and results in the detected energy spectrum as a 
continuous count distribution.  When gamma photons are scattered in an angle 
approximately 1200 – 1800, more gamma energy is transferred to the electron, and  as a 
result more energy is deposited within the crystal material. This is called the Backscatter 
Peak [9, 38, 39].  
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In our experiments Lead (Pb) was used as a shielding material by surrounding the detector 
system in order to minimize the effects of background γ radiation. In Pb collimator the 
photoelectric absorption occurs which leads to detection of Characteristic X-Rays. This is a 
result of the de-excitation of atoms in exited states, which exist only for a short time period 
when the orbital electrons change their configuration. When the atom reaches the lowest 
energy state, the energy is released in the form of Characteristic X-Rays or Auger electrons 
[39]. Furthermore, the characteristic X-rays can also be produced in NaI(Tl) scintillation 
detector, as a result of x-ray escape resulting to a peak at a lower energy at about 30 keV.  
 
 
Fig. 1, Schematic illustration of NaI(TI) detector and γ-ray interaction processes during  measurements  
When the released electrons pass through matter they lose their kinetic energy as given by the 
stopping power: [38, 39] 
                                                                            𝑆𝑝 = −𝑑𝐸 𝑑𝑥       (1) 
A transformation of the deposited electron energy into light (photons) occurs since upon de-
excitation light is produced. This light is reflected towards the photocathode of the PMT. The 
 11 | P a g e  
 
scintillation photons passing through the photocathode eject electrons by the photoelectric 
effect, and then in a continuous process, the electrons pass through the chain of dynodes. In 
the PMT the electrons are accelerated by a strong electric field, causing the release of other 
electrons when they collide with the dynodes. When the last dynode is reached the electron 
cascade is transferred to the anode collector which is connected to the charge preamplifier 
which enables the conversion of the collected charge into a voltage pulse [38, 39]. As a final 
process the pre-amplified pulse through the linear amplifier is shaped and amplified. The 
number of photons detected in the scintillation crystal is proportional to the amount of γ-ray 
energy which is absorbed in the NaI(Tl) crystal [38.39]. The pulse decay time is about 0.25 
microseconds in NaI(Tl) detector and the convertion into a pulse is 0.5 microseconds. In the 
analog-to-digital converter the pulse height is registered as counts corresponding to a specific 
deposited photon energy, which is displayed in the MCA [27, 38, 39].  
The NaI(Tl) detector system used for conducting experiments was 3” x 3” Harshaw/Fllrol type 
12S12/3A Serie CP-488 (660 V). 
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          II.2   The HPGe Detector System  [9, 10, 38, 39, 44]   
The HPGe detector with high capacitance is used for detection of γ-rays. The Germanium crystal 
serves as a semiconductor, where an electronic signal is transmitted via mobile or “free” 
electrons and holes. If the crystal is doped with a small amount of impurity atoms the number 
of charge carriers increases. When a doped semiconductor can contain excess holes, it is then 
called a p-type detector. When it contains excess free electrons it is known as n-type detector. 
When doped Ge and n-doped is put together, an electric field occurs in a small region near the 
joining, due to diffusion of electrons and holes. This region is called the depletion layer.  
By putting a reversed voltage, meaning to couple the negative voltage to p-type region and 
positive voltage to n-type region, the depletion layer can be enlarged up to the Zener-limit. It is 
this layer which is used for detection of γ-rays. Due to the high purity Ge a relatively large 
voltage can be applied, creating a relatively large detector volume.  
If not cooled, the excited electrons in the Ge crystal are followed by further excitation as a 
result of thermal energy. The HPGe detectors are mainly cooled by liquid nitrogen (LN2)- in a 
thermal contact which allows cooling it at around -2000 C, in order to reduce the thermal 
charge carrier generation (background noise) to a reasonable level. Their operation is thus 
mainly at low temperatures.  
There are several types of HPGe detectors, depending on the configuration, energy range to be 
detected, shape of Ge crystal, applied voltage and γ-ray charge collection, for instance: ultra 
LEGe, Low energy Ge, broad energy Ge, coaxial Ge, reverse electrode and XrRa. 
The incoming γ-rays gives their energy to electrons and during the trajectory of the electrons, 
inelastic collisions with atomic electrons will cause excitations of the electrons in the valence 
band to the conduction band. Secondary electrons thus create a bunch of electron hole-pairs 
during their trajectory in the detector. These are collected using an electric field producing a 
charge which is collected by the pre-amplifier. The holes travel in the opposite direction and 
can also be measured. The pulse size is proportional to the collected charge which is 
proportional to the deposited energy. The results are generated in the form of spectroscopic 
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data. Since the energies of γ-rays are known, this can provide useful information on the 
composition of an unknown sample.  
The principles of operation thus includes the collection of the charge by the high voltage from 
the pre-amplifier, the produced charge from γ-radiation (from sample to the detector), 
amplifies it and produces a pulse “with amplitude proportional to the total charge”. The 
amplifier takes the pulse signal from pre-amplifier filters and shapes it in order to enhance the 
signal to noise-ratio. This also helps in avoiding the overlapping between the produced pulses. 
After the production of the analog signal from the detector by the amplifier, it will be converted 
into a digital signal using the ADC (analogue-to-digital converter) and finally it will be registered 
in the MCA software. The high-power voltage supply applied for HPGe detector system ranges 
from +1000-5000 V.  
The most important characteristics for these kinds of detectors are the energy resolution for 
detection of small mass energy samples, data analysis with high level of precision and tolerance 
against high count-rates.  
The HPGe detector used for our experimental purpose is an- ORTEC Detective DX, a p-type 
HPGe detector with coaxial construction, with crystal nominal dimensions of 50 mm diameter 
and 30 mm deep. It was cooled with electricity.  
The crystal shielding material is from steel with dimension of 5mm, and the Input power from 
10 to 17 V DC 30 W, and operation temperature ranges from 0°C up to 40° C.  
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III. Decay of 177Lu  and 177mLu  
The radionuclide 177Lu labeled to DOTATATE is used in clinical trials for in vivo therapy of 
neuroendocrine tumors. [2, 14, 16, 19]. Because of its nuclear decay characteristics and 
chemical properties [16], 177Lu has shown impact on the renal toxicity [7] but in comparison to 
other available radionuclide, such as 90Y it is considered to be a radionuclide which is better 
tolerated by the kidneys [10, 15].   
The half life is 6.64 days [6, 18, 20] whereas other reported 6.734 days [17, 21], it emits β- 
particles with maximum energy of 498.3 keV with a penetration range of 2mm [13, 21] and 
decays to  stable 177Hf  (through excited states of 177Hf). The decay scheme is shown below: 
[14,15, 18 20].   
      
Fig.2, Reproduced decay scheme of 177Lu from Nuclear Decay Data Scheme [42]. (Marked in red color 
are the gamma-energies used for measurement). 
As seen from the decay scheme, its disintegration is mainly done by β- emission in 79.4% to the 
ground state of 177Hf with maximum β- energy of 498.3 keV. Moreover, there is also a β- 
emission in 11.61% to 321.31 keV, in 9.0% to 112,94 keV while only a small fraction of 0.06% to 
249.67 keV. As consequence of de-excitation of the excited states, gamma-radiation is emitted 
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and the most intense gamma rays are at energies of 112.94 keV and 208 keV, with abundances 
of 6.4% and 11%, respectively [6, 12, 13, 16, 18, 42]. These are useful for imaging purposes 
which enables a proper monitoring of in vivo localization of the injected 177Lu-DOTATATE as 
well as reliable dosimetric estimations [12, 14, 18, 20, 42]. 
As it decays by β- decay it emits electrons which have a short path length, i.e they deposit their 
energy locally thus giving a high absorbed dose [13]. 
The manufacturer specification for the 177Lu radionuclide purity is >99%, while <0.05% is 177mLu 
and 0.01% of other impurities with a specific activity of 7400 MBq at the calibration time [22]. 
For this purpose the decay scheme and further investigation of the 177mLu activity within 
the 177Lu sample, has been made [15].  The decay scheme of 177mLu is shown below:   
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Fig. 3, Decay Scheme of 177mLu reproduced from Nuclear Data Decay Scheme [42]. (Marked in red are 
the gamma energies used for measurement). Note that the daughter product of the isomeric transition 
is 177Lu which in turn decays through the scheme depicted in Figure 2, to 177 Hf.  
Therefore, the administered activity contains both 177Lu and 177mLu at unknown relative 
amounts. 177mLu decays partially to 177Lu at 21.7% by isomeric transition through γ-emission, 
and partially at 78.3% by β-decay to 177Hf which also is the decay product of 177Lu.  The half-life 
of 177mLu is 160.4 days.  
The 177mLu can be used for γ-ray efficiency calibration purposes as a standard manner because 
of its emission probability [10]. Its half life of 160.4 days is considered to be relatively long and 
by the isomeric transition 177Lu is also produced at decay.  
Thus, 177mLu decays partially through β-decay to 177Hf, with a long half-life of 160.4 days and 
partially through γ-emission, towards the 177Lu ground state which subsequently decays to 
stable 177Hf through β-decay. As a result of the decay of 177mLu, the amount of 177Lu is thus 
built-up. The total activity (𝐴𝑇𝑜𝑡𝑎𝑙) as a function of the time that (t) has passed after 
radionuclide production (t ) can be written as: [18] 
   𝐴𝑇𝑜𝑡𝑎𝑙(𝑡) =  𝐴177𝐿𝑢,1(𝑡) + 𝐴177𝑚𝐿𝑢,(𝑡) + 𝐴177𝐿𝑢2,(𝑡)   (2) 
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where 𝐴177𝐿𝑢,1(𝑡)  and 𝐴177𝑚𝐿𝑢,(𝑡) are the activities of 177Lu and 177mLu that are directly 
produced at radionuclide production, and 𝐴177𝐿𝑢2,(𝑡) is the 177Lu activity that is decay product 
of 177mLu. 
The Activity of 177Lu, as being built-up during the decay of 177mLu, is given by the equation for 
serial decay [19, 46].  
The total Activity is thus given by: 
𝐴𝑇𝑜𝑡𝑎𝑙(𝑡) =  𝐴177𝐿𝑢1,0 𝑒−𝜆177𝐿𝑢𝑡 + 𝐴177𝑚𝐿𝑢,0𝑒−𝜆177𝑚𝐿𝑢𝑡 +  𝐴177𝐿𝑢2(𝑡) = 𝐴177𝐿𝑢1,0 𝑒−𝜆177𝐿𝑢𝑡 +
𝐴177𝑚𝐿𝑢,0𝑒−𝜆177𝑚𝐿𝑢𝑡 + 0.217 𝐴177𝑚𝐿𝑢,0 𝜆177𝐿𝑢𝜆177𝐿𝑢−𝜆177𝑚𝐿𝑢  (exp(−𝜆177𝑚𝐿𝑢𝑡) − exp (−𝜆177𝐿𝑢𝑡)    (3) 
where 𝜆177𝐿𝑢 and 𝜆177𝑚𝐿𝑢  are the physical decay constants and 𝐴177𝐿𝑢1,0 and 𝐴177𝑚𝐿𝑢,0 are the 
activities of 177Lu and 177mLu, respectively, directly after radionuclide production. The factor 
0.217 in the last term is the probability for the isomeric transition in the decay scheme of 177mLu 
(fig.3). 
It is important to note that because of the complex decay scheme, the decay of 177mLu needs to 
be well characterized and also γ-ray emission to be accurately determined [19]. 
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            III.1 Production Routes of 177Lu 
Depending on the required Specific Activity (As) , two production routes are applicable for the 
production of 177Lu, both involving neutron activation processes: [15, 16] 
1) The direct production route based on neutron irradiation of Lutetium targets [16]. 
This is an easier production path of 177Lu, and is used for production of the 177Lu that 
is labeled to peptides in the activities from 7GBq to 9GBq [22]; 
2) The indirect production route , necessitating a chemical separation of 177Lu from the 
target [16] 
Which method is used for the production of 177Lu depends on the required Specific Activity, As. 
The chemical impurities may affect the efficiency of the radiopharmaceutical labeling process 
and it can therefore lead to a decreased radiopharmaceutical labeling efficiency [16]. Thus, with 
higher As the radio-labeling of the tumor specific antibodies or peptides can be more efficient, 
resulting in smaller amounts administered substance, which assures that the tumor uptake is 
not saturated due to filled binding sites for the tracer in the tumor cells [16]. Therefore, the 
chemical purity can be important for the radionuclide used for therapeutic purposes.  
1) The direct production route involves the nuclear reaction with neutron bombardment 
of 176Lu, as follows: [6, 14, 15, 16]: 
    176Lu( n, γ)-> 177Lu       (4) 
This method for the production of 177Lu, enables higher As for the radionuclide [14], while only 
a small amount of impurity in the form of 177mLu and small fraction of impurity of 176mLu (half-
life 2.64 h) is generated [6, 15]. For this production route there is a need for enriched target 
material because of natural abundance of approximately 2.6% of the 176Lu. The only limitation 
associated with this production route is the c.a of 177Lu preparations which can be obtained, 
because of the stable isotopes of 176Lu.  
2) The indirect production route of 177Lu involved the nuclear reaction of 177Yb which is 
produced by the bombardment of 176Yb by a chemical separation in order to produce a 
higher As of 177Lu, as follows [8, 16]: 
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176 Yb (n,γ) 177 Yb (β-)  177Lu      (5) 
177Lu is thus obtained free c.a from β-decay of 177Yb, produced by the neutron capture of 176Yb 
(which has low cross section), in the nuclear reactor. In order to obtain the n.c.a. 177Lu with 
maximum As, Lutetium should be chemically separated from the Yb target [16]. 
The indirect production route is based on the neutron irradiation of Ytterbium followed by the 
radiochemical separation of 177Lu from the Ytterbium isotopes [16]. The requirements for the 
separation of 177Lu includes:  Reduce the Yb amount to approximately < 100 ng; High chemical 
and radionuclide purity of 177Lu , to be obtained from the radiopharmaceuticals (LuCl3 in 0.05 
M HCl) [16]. A fast and reliable separation method should be performed. There are several 
separation processes but will not be discussed in this report at this stage [16].  
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IV. Internal Radiation Dosimetry 
The radioisotope used for medical depends on its purposes: [39] 
• Diagnostic purposes (high γ-rays yield which can penetrate out from the body and as a 
result are detected/imaged; Also minimizes the radiation dose to tissues in patients; γ-
rays with E=50-350 keV and minimal emission of particles is associated. 
• Therapeutic purposes (mainly particles emitters for instance β- particles so they can 
deliver at a high localized radiation dose to the tissues adjacent to the decay for example  
tumors accumulating the radio-labeled tracer. Emission of γ-rays allows for imaging and 
dosimetry.  
The determination of the tumor uptake of 177Lu and absorbed dose to the tumors and risk 
organs require knowledge of patient specific time-variated biodistribition of the activity in the 
body [3]. In order to obtain accurate dosimetric calculations the individual renal volume, dose 
rate and fractionation play an important role and this enables the prediction of risk for renal 
function difficulties [35]. Doses are based on the volume and the average activity uptake values 
over the ROI, using the planar imaging conjugate view method. With this method the only 
possible outcome is the mean dose to the organ (by fitting the time activity curve to the ROI 
data) and using the resulting cumulated activity as an input for dosimetry calculation (for 
instance, OLINDA dosimetry computer code), in order to obtain the organ dose estimations and 
the dose distributions [10, 36]. For this purpose, the Gamma Camera for the WB imaging and 
SPECT and CT is used at Lund Hospital University, as illustrated below:  
    
 
    
 
Fig. 4, Gamma Camera 
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The technical specifications for this gamma camera are as follows: [45] 
GE Millennium Discovery VH, CT Hawkeye, which enables the measurement at different angles 
from 90° – 180° detector rotation in order to achieve a good scanning efficiency. The camera 
has two detector heads. The scintillation detectors are flat NaI(Tl) crystals 40cm x 50cm (which 
register the number of counts in the energy window. These detectors have an energy range 40 
keV-520 keV and a crystal thickness of 1” (25.4mm). There are 59 PM tubes. The camera is 
equipped with different collimators, which are used depending on the radionuclide gamma 
energy: for measurement of 177Lu a medium energy collimator is used as suitable for 208 keV. 
The camera allows for planar whole-body scanning in anterior and posterior views, as well as 
SPECT (Single-Proton-Emission-Computed Tomographic) scanning.  
The x-ray CT image is used to delineate the patient anatomical structure and creating the 
attenuation maps used for attenuation correction purposes. The x-ray tube generates x-rays on 
Tungsten targets which are filtered by 0.5 mm copper. The data acquisition is conducted by 
remote control equipment, and the patient table allows the adjustment of the patient position 
and scanning of anterior and posterior WB scans.  
The main purpose for Gamma Camera imaging is to determine the radioactivity distribution 
within different organs. The function of the Gamma Camera is to register the number of counts 
resulting to an image. Only a small fraction of the emitted radiation is detected [41]. During the 
image acquisition process some of the photons will be able to penetrate through the collimator 
(via holes) and registered in NaI(Tl) detector as a number of counts. Thus, the photon energy 
hits the NaI(Tl) crystal and the PM tube collects and positions the pulses. There are also 
photons that scatter.  
The medical images are taken with 2D planar WB scanning for determining the specific activity 
distribution (with resolution 5-10mm) [4]. The method for image acquisition and data analysis 
also includes the use of SPECT/CT images which allows 3D measurements of the activity uptake 
[8,10].  
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The x-ray equipment is used in this context for determining the transmission of x-rays through 
the patient. Generally for an absorbing material with thickness X (cm), the transmitted amount 
of photons, N in relation to the incoming number of photons N0, can be described as: 
     𝑁
𝑁𝑜
= 𝑒−𝜇𝑋      (6) 
where µ is the linear attenuation coefficient (1/cm) valid for a particular photon energy and 
absorber material.  The CT equipment makes an image that reflects the distribution of µ in the 
patient, and can thus be used to correct the gamma camera image for photon attenuation. A 
whole body planar x-ray image can also be acquired, a so called scout image, which is used for 
attenuation correction of the whole-body scans from the gamma camera measurement.  
The quantitative images are sufficient for defining an accurate localization of the activity in 
organs of interest and modeling, in order to obtain the cumulated activity within ROI and be 
able to estimate the absorbed dose [30]. The dosimetric calculations for activity determination 
of the absorbed dose by using models and data, remains essential.  
The Absorbed Dose is the energy (E) deposited per unit mass (m) and is measured in the unit of 
Gray (Gy) with 1Gy=1J/kg [39]. The Absorbed Dose is defined as:  
     𝐷 = 𝑑𝐸
𝑑𝑚
 � 𝐽
𝑘𝑔
= 𝐺𝑦�                          (7) 
According to MIRD which has developed the model for the Absorbed Dose used in internal 
dosimetry is equal to the integral of Dose Rate (?̇?) over period of time (t), meaning that it varies 
with Activity (A) which varies with time (t):  [29]  
 𝐷� = ∫ ?̇?(𝑡)𝑑𝑡∞0 = ∫ 𝐴(𝑡)  ∙ 𝐷𝐹 (𝑇 ← 𝑆)𝑑𝑡 = ?̃? ∙ 𝐷𝐹(𝑇 ← 𝑆)∞0                      (8) 
where 𝐷� is the mean absorbed dose (Gy), ?̃? is the total cumulated activity (MBq-h), DF is the 
mean absorbed dose to the target tissue T per unit cumulated activity (Gy/MGq-h) in an activity 
located in source tissue S [29]. In the MIRD nomenclature DF is instead called S-factor: DF is the 
same value but in this report termed according to OLINDA dosimetry software. Term ?̃? covers 
the metabolic factors and physical decay and depends on the source organ and biological 
elimination of 177Lu by the source organ. DF factor depends on the emission characteristics 
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from the physical decay of radionuclide, the range of emitted radiation and size of organ [29]. 
The values of DF are determined for standard phantom geometries specific for gender and age. 
They are defined as:  
 𝐷𝐹(𝑇 ← 𝑆) = ∑ 𝑦𝑖𝐸𝑖𝛷(𝑇←𝑆)𝑖
𝑚𝑇
 (9) 
where y is the emitted number of radiation particles, E is the particle energy, and 𝛷 – absorbed 
fraction of the emitted energy i.e. the absorbed energy in target tissue T from decay in source 
tissue S.  
Thus the absorbed dose is calculated through the MIRD schema [21]. The activity in different 
organs is calculated using the images obtained from Gamma Camera. The time-activity curves 
for different organs allow for calculation of the cumulated activity by curve fitting [21] and 
subsequent integration over time. The estimates of the Absorbed Dose are obtained using 
LUNDADOSE software, which has the kinetic curve fitting and DFs for patients, based on gender 
and age [21,33].  
From SPECT/CT images, the absorbed dose rate can be calculated more accurately. The 
principle for estimation of the absorbed dose is similar to that described above. However, since 
the planar scans provide information that is not resolved in the depth dimension, whereas 
SPECT provides 3D information, the SPECT based information is superior.  
At Lund University Hospital 4 planar scans are acquired after the administration of 177Lu – 
DOTATATE and calculations performed using LUNDADOSE. Also SPECT/CT imaging is performed 
at 24 hours after administration.  
The protocol for patient measurements used at using gamma camera is as follows: 
 20% energy window centered over the 208 keV photo-peak in the energy spectrum  
o Whole body scans performed at four time points. The details below:  
 Scan length: 200 cm 
 At day 0 (0.5 h after the administration): Scan speed 20 cm/min, 
acquisition time, 12 min  
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 At day 1 (24 h after the administration): Scan speed 10 cm/min, 
acquisition time: 24 min  
 At dat 1 (24 h after the administration): SPECT/CT imaging 
 At day 4 (96 h after the administration): Scan speed 10 cm/min, 
acquisition time: 24 min 
 At day 7 (168 h after the administration): Scan speed 10 cm/min, 
acquisition time: 24 min 
The Absorbed Dose in kidneys is determined based on a combination of the time series of time-
activity obtained from planar whole-body scans, and the dose rate determined from SPECT/CT 
on one occasion (24 hours). The TB activity is determined from the whole-body scans.  
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V. Experimental Geometry, Methodology and Data Analysis  
The experiments have been carried out in a laboratory at the Department of Medical Radiation 
Physics, Lund University using the experimental set up system of NaI (TI) 3” x 3” (74mm x 74mm 
scintillation crystals) detector system at Voltage at 750 V, with a construction described in a 
Chapter II.1 above. For some of the measurements the HPGe detector system was also used in 
order to make a comparison of the Activity results. In the figure below an illustration of used 
detector system, is presented. Both detectors, NaI(TI) and HPGe detector were aligned to the 
MCA software configuration, for data acquisition for further analysis [23].    
            
Fig. 5, Experimental Setup for patient measurements  
For the NaI(TI) detector Lead (Pb) was used as a shielding material with length 16.5 cm and 
thickness 2 mm, in order to obtain a better angular resolution and less impact of Compton 
scattering in surrounding material, in the room. The measurement of γ-ray spectroscopy has 
been performed using a well defined geometry by setting an appropriate distance between the 
source and the detector crystal. The distance has an impact on the precision of the results from 
the analysis, and the uncertainty associated with the distance [9]. During the experimental 
work measurements of selected reference sources and 177Lu samples have been performed at a 
source-detector distance of 74 cm. The data acquisition time was normally set to 300 s. Prior to 
every measurement the background was measured for 40 000 s, and its count rate has been 
subtracted from the count rate of source measurement. For instance, obtained spectra of 137 Cs 
are shown in the plot below: 
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 Fig.6, CPS vs Energy [keV] for 13Cs with NaI(Tl)detector (upper panel) and HPGe detector (lower panel). 
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The measured count rate in background also has an impact on the results from the data 
analysis. The most prominent peak in the practically performed measurements was the γ-rays 
from Potassium (K) as a result from cosmic radiation (contribution to background), was 
detected at 1461 keV. This had no impact on the results from the data acquisition of reference 
sources and 177Lu, because of its energy which did not interfere with the γ-peaks of the sources 
[9]. The identification of the γ-ray energies as a function of energy, more specifically, 
identification of the γ energies close to 177Lu and 177mLu has been made, identifying the sources 
of:  57Co, 133Ba and 137Cs to be the most appropriate to be used, in order to cover the range of γ-
ray energies emitted by 177Lu and 177mLu, at 113 keV, 208 keV for 177Lu, and at 378 keV and 418 
keV for 177mLu, respectively. 
Measurements of the above mentioned reference sources were performed for determination 
of the Activity, detector photo-peak Efficiency for both detector systems. (more information on 
the outcomes will be presented in a later chapter of this report). Data analysis for each 
experiment has been made by two methods: automatically (results obtained from Maestro 
analysis software) and by manual analysis in Excel programme. The experimental data and a 
detailed table on gammas, beta energies and x-rays for each of the used radioactive sources are 
available in Appendix I and Appendix II, respectively at:  
https://www.dropbox.com/s/zihjh3jtwbgocts/APPENDIX%20I%20%20DATA%20on%20Measure
ments.xlsx  and https://www.dropbox.com/sh/x2eoyms55057or0/AMGh3Phu1J.  
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VI. Detector System Energy Calibration 
The energy calibration of the detector system was performed by using the identified reference 
sources in order to obtain the channels in the MCA relative to the energy absorbed in the 
detector upon interactions by the photoelectric effect, by implying a linear relationship 
between the deposited energy and channel number [39]. The calibration of the NaI(TI) detector 
system was performed by using the most suitable γ-ray energies of identified reference sources 
close to those emitted by 177Lu and 177mLu [27]. For the purpose of energy calibration, the 
radioactive sources of 57Co at 122 keV and 137Cs at 662 keV were used, because these 
radioisotopes emit closer γ-ray energies to that of 177Lu at 113 keV and 208 keV, and to that 
of 177mLu  at energies 378 keV and 418 keV, respectively. Meanwhile, 133Ba at 356 keV has been 
used for verifying the stability of the detector system. In some of the measurements the energy 
calibration proved to be not very stable, causing discrepancies in the peak values [27]. The 
spectra of the photo-peak at known energies have been acquired, caused by the photoelectric 
effect in the NaI(TI) crystal. As already cited in this report the spectrum shape may also vary 
and be influenced by other possible effects/processes which might occur during the γ-ray 
energy absorption [28]. 
In the figure below a picture illustrating the sources used for measurements, using both 
detector systems,  is presented: 
                       
       Fig 7, Reference sources and 177Lu samples 
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The Table of Radioactive sources for the three of above mentioned radioactive sources used, 
show the properties as follows: [9, 42] 
 57Co with a half-life of 271,79 d at 122,06 keV (abundance 85,6%)   
 133Ba with a half-life of 10,5 y at 80,99 and 356,01 keV (abundance 34,6 % and 62,05%) 
 137Cs with a half-life of 30,07 y at 661,65 keV (85,1%) 
From the known gamma-energies of the above listed radionuclides, the offset and slope were 
determined using the equations: [25] 
𝑆𝑙𝑜𝑝𝑒 = 662 𝑘𝑒𝑉 − 122 𝑘𝑒𝑉
𝑝𝑒𝑎𝑘 𝑐ℎ𝑎𝑛𝑛𝑒𝑙#662 −  𝑝𝑒𝑎𝑘 𝑐ℎ𝑎𝑛𝑛𝑒𝑙#122   � 𝑘𝑒𝑉𝑐ℎ𝑎𝑛𝑛𝑒𝑙#� 
Offset= Energy @ channel zero [keV]       (10) 
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VII. Determination of Energy Resolution 
The energy resolution for the detection process of γ-rays reflects an uncertainty in the 
determination of the γ-ray energy. It depends on random fluctuations in the γ-ray absorption 
and light emission, light collection in photocathode, production of photoelectrons, collection of 
photoelectrons and multiplication by PMT dynodes [24, 39].  
The energy resolution is different for different photon energies. From the spectra analysis, the 
results show that the FWHM is smaller for HPGe detector comparing to NaI(TI) detector. Thus, 
the HPGe detector offers a very good resolution and is useful for nuclide identification even at 
small energies. The value for the FWHM corresponds to the resolution of the NaI(TI) and HPGe 
detectors. It describes how useful the detector is for separating between two energy peaks, in 
order to identify the nuclide (based on energy), particularly for HPGe detector. The higher the 
count rate the better energy resolution [27].  
The basic parameters for the energy resolution of the detector are: the peak shape and Full 
Width at Half Maximum (FWHM) as a function of ϒ-ray energy [28]. The energy resolution (ΔE) 
of the detector has been determined by using the equation: 
     ∆𝐸 = 𝐹𝑊𝐻𝑀
𝐸
 ∙ 100%                  (11) 
where E is the γ-ray energy. Theoretically, the determined γ-ray energy is governed by Poisson 
statistics. The uncertainty in the determined  γ-ray energy, and thus the FWHM, is then 
proportional to √𝐸, and the energy resolution to ∆𝐸~ √𝐸
𝐸
= 1
√𝐸
. From a measurement of the 
energy resolution at one γ-ray energy, for instance for 137Cs at 662 keV, giving  ∆𝐸662, the 
energy resolution at another γ-ray energy (E) can be estimated as: 
     ∆𝐸𝑚𝑜𝑑𝑒𝑙 = ∆𝐸662  ∙ �√662√𝐸 , �      (12) 
For this purpose, three methods were used for the determination of the energy resolution for 
both detector systems: 
1) Manual calculation (data obtained manually)  
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Here, the maximum number of counts in the photopeak energy window has first been 
determined. Then the scatter background in 3 channels immediately to the right and left of the 
photopeak energy window has been determined to be used for the determination of the 
average number of counts in scattered background and the peak height above the background. 
The counts at half maximum were then calculated. Finally, the width of the photopeak for the 
counts at half maximum was determined. For 57Co and 137Cs peak shapes allowed for identifying 
the FWHM, while for 177Lu a linear interpolation of the counts versus energy data was 
performed particularly for the HPGe detector measurement where the energy peaks were 
narrow.  
2) Maestro calculation (automatic data obtained by the Maestro software) and  
3) 137Cs as a reference/model calculation (taking into account that 137Cs has the 
most appropriate shape as a full peak for this purpose).  
The results obtained are shown in the plots below, resulting in some variability in the used 
methods, especially for Maestro calculation for 208 keV: 
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 Fig, 8, Energy Resolution of the detector systems, a) NaI(TI) detector, b) HPGe detector 
The energy resolution for NaI(Tl) detector particularly for 177Lu has encountered an error in the 
FWHM value resulting to be only 4.11 as an arbitrary value, resulting to a non-appropriative 
energy resolution of NaI(Tl) detector, particularly for 177Lu at 208 keV, as shown in the plot 
above, under a). By taking into account the interactions and amplifications as well as 
encountering the contribution from each peaks for expansion of the full energy peak at 208 
keV, might have lead to this error result, in this particular sample. However, from the 
measurements of other several 177Lu samples the FWHM value was reasonable, but still in this 
particular 177Lu sample used in our experiment for determining the energy resolution, has lead 
to bringing the attention that such errors might occur, therefore special attention should be 
made for reaching the best possible FWHM value in order to avoid an inappropriate energy 
resolution determination. 
The detailed results on the estimation of energy resolution for the both detector systems of the 
specific measured radionuclide are shown in the Appendix III.  
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VIII. Activity Determination for Reference Sources and 177 Lu samples 
Measurement of radioactive reference sources in point source geometry have been performed 
at different occasions. The Activity of radioactive sources has been estimated using the 
equation:   
     𝐴 = 𝐴0 ∗  𝑒−λt  [Bq]                                 (13) 
The activity for reference sources and several 177Lu samples was determined, as shown in the 
table below: 
Source 
 
Original 
Activity 
Original 
Date 
Elapsed 
time 
Measurement 
NaI(Tl)   
15.05.2012  
A(MBq) 
 
Elapsed 
time 
Measurement 
HPGe 
26.06.2012  
A(MBq) 
57Co  22.2 MBq 01.02.2006 2296 d 0.06 2338 d 0.06 
133Ba 4.31 MBq 25.03.2002 3705 d 2.21 3747 d 2.18 
133Ba 8.62 MBq 25.03.2002 3705 d 4.41 3747 d 4.37 
137Cs 346 kBq 8.2003 9.5 y 0.28 9.5 y 0.27 
Radioactive  
source 
A0  [MBq] Original 
date 
Elapsed time A [MBq] 
177Lu 730 MBq 24.04.2012 1 h 726.82 
177Lu 730 MBq 24.04.2012 23 h 660.35 
177Lu               730 MBq        24.04.2012          43 h                    605.21 
 
Table no. 1, Activity determination for radioactive reference sources and 177Lu samples 
As indicated in the table above, measurements were performed at different time points, so that 
the activities used for measurements were slightly different. The Activity calculation sheet is 
attached to this report in Appendix IV. 
In equation (3) we consider only the first two terms: the activities of 177Lu and 177mLu and 
estimate them, on the basis of 7 days and one month after injection (which is normally one or 
two days after radionuclide production). Considering that the activity of 177mLu at the time of 
production, according to the producer is only a small fraction 0.05% of the total amount, for 
instance in a sample of 7400 MBq, where 0.05% is 177mLu, being 3.7 MBq one hour after the 
production, with 177Lu there will be a drop to approximately 3597 MBq for 177Lu one week after 
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the injection, but still the Activity for 177mLu will remain at a level of 3.6 MBq. The activity drop 
will be with different for 177Lu and 177mLu, due to their half-lives. 
    
   Fig. 9, Activity for 177Lu and 177mLu at different time points after production 
From the calculation data after one month from the production day, the activity of 177Lu will be 
304 MBq while for 177mLu, it will be 3.2 MBq. From the plot below one can see that the time 
point when 177Lu “matches” 177mLu is at day 75, and this is the time point when the 177mLu starts 
to dominate. 
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     Fig. 10,  Activity vs Time after production for 177Lu and 177mLu in logarithmic scale 
This estimation would help us compare at a later stage the TB Activity at different time points, 
as shown in Appendix V.  
If we consider all three terms in equation (3) i.e 177Lu1, 177mLu and 177Lu2 and assume that the 
amount of 177mLu at the time of production is 0.05% then based on the decay data and their 
half-lives, one can see that the activities of the three components, normalized to the total 
activity, following the shape in the plot below:  
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Fig. 11, Fraction of Total Activity including each of the contributing terms in equation (3), 177Lu1, of 
total, 177mLu of total and 177Lu2 of total. 
 
If we for each of the contributing components in equation (3) insert the number of 208 keV 
gammas that are emitted for 177Lu and 177mLu decays, which are 11% and 57.7%, respectively, 
then the amount of 208 keV gammas can be calculated. The fraction of the total number of 208 
keV gammas that are emitted from each component is shown in the plot below: 
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Fig. 12,  Fraction of Total 208 keV gammas including each contributing terms  177Lu1 of Total, 177mLu of 
Total and  177Lu2 of Total 
In order to determine the respective amount of 177Lu and 177mLu from the spectra that were 
measured in patients, this has to be taken into account. The formulae for these considerations 
have been compiled by the supervisors and are given in Appendix VI. Measured spectra for a 
point source of 177mLu in air with both detector systems are shown below: 
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Fig. 13, 177mLu measurement with NaI(Tl) and HPGe detector systems 
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IX. Determination of Photo-peak Efficiency  
The detector photo-peak efficiency describes the count rate obtained per photon that impinges 
to the detector and it varies with γ-ray energy. It was determined for measurements of 
reference sources, by identifying the γ-rays coming from the radioactive source [9]. The count 
rate analysis for all measurements has been performed by determining the detected count rate 
from the detector as: net area under the photo-peak divided by the measurement time, divided 
by the gamma fluence rate (which is the number of photons that impinges to the detector 
surface per unit time). The gamma fluence rate has been calculated from the source activity, as 
the number of emitted photons with the selected energy per decay, abundance of the γ-ray 
photon, the distance of the source from the detector, and the area of the detector front surface 
[38, 39]. Background measurements were performed prior to the source measurements and 
background count rate was subtracted.  
More specifically, the determination of: 
 Gross area CPS – The sum of background corrected CPS  under the photo-peak area 
 Average scatter background CPS (l &r)   - Average count rate in 3 channels located to 
the left (l) and right (r) of the photo-peak.  
 Scatter area  -  Channels  multiplied by the average scatter background CPS (l+r)/2  
 Net area CPS -  Gross area minus scatter area (Rpeak) 
 Energy Calibration – used to determine the offset and slope as described above 
In order to calculate the Net Area CPS (Rpeak) the scatter area (which is the sum of “triangle” 
and “rectangle”) was subtracted from the gross area.   An illustration as follows:            
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                                               Fig. 14, Gross area CPS and Net area CPS. 
The photo-peak efficiency (ϵ) determination has been calculated by using the net area CPS 
(Rpeak) for the photo-peak of different radioisotopes, the source-detector distance (D), and 
specifications on n-gammas for each of the radioisotopes, activity (A), and front surface of the 
detector (S)  using the equation: [38]  
   𝜖 = 𝑅𝑝𝑒𝑎𝑘
𝐴 ∙ 𝑛𝛾  4 𝜋 𝐷2𝑆      (14) 
The photo-peak efficiency (ϵ) valid for selected measurement geometry which is a point source 
at a relatively large source-detector distance. The results obtained on photo-peak efficiencies 
for both detector systems on measured radioactive sources are shown in the plots below: 
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Fig.15, Plots on Efficiency determination for: a) NaI(TI) detector and b) HPGe detector determined for 
reference sources, for which the efficiency for gamma peaks of 177Lu and 177mLu were estimated, as 
indicated by red dashed lines.  At a later stage in the project a calibrated 177Lu sample was obtained as 
indicated by ‘New 177Lu calibrated sample’. 
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As one can see from the plots above, there is a decrease in the photo-peak efficiency increasing 
with the γ-ray energy. 
The HPGe detector shows to have a smaller efficiency comparing to NaI(TI), due to the fact that 
NaI(TI) has higher probability for the detection of γ-radiation. Even though NaI(TI) has poor 
resolution it is more efficient comparing to the HPGe detector. Furthermore, the scitillation 
detection enables a high detection efficiency for different types of radiations, and capability to 
measure energy spectra with a high counting rate. Scintillators in γ-spectrometry provides a 
high detection of efficiency; large Z and large density of the crystal with a high light output [38, 
39]. 
As indicated above the variation of the detectors efficiencies using different radioisotopes at 
different energies (keV) has been determined. Reference to this, an approximate determination 
of the detector system efficiency for detecting the 177Lu and 17mLu has been determined.   
The measurement of reference sources at different photon energies performed with the NaI(TI) 
detector system, the results of the net area count per second (R) are shown in Appendix VII to 
this report.  
The results of the efficiency for both detector systems in % are shown in the table below :  
Radioactive 
source 
Energy  
[keV] 
Efficiency  
NaI(Tl) 
Efficiency  
HPGe 
Efficiency of new 
calibrated 177Lu 
sample 
57Co 122 0.690 0.276 NaI(Tl) HPGe 
133Ba (1) 356 0.435 0.090 0.649 0.411 
133Ba (2) 356 0.444 0.094  
137Cs 662 0.379 0.054 
177Lu 208 0.61 0.293 
177Lu 378 0.419 0.121 
177Lu 418 0.41 0.11 
  Table no.2, Efficiency of the radioactive reference sources and 177Lu , 177mLu 
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X. Determination of Standard Deviation in Efficiency 
The standard deviation σϵ shows the variation of the obtained efficiency from measurements as 
an average mean. The calculation of standard deviation for performed measurements has been 
evaluated using the expression, by derivation as shown in Appendix VIII.  
𝜎𝜖
2 = � ∈ 𝐴𝑈𝐶𝑛𝑒𝑡�2 ∙  𝜎  𝐴𝑈𝐶𝑛𝑒𝑡2 + �2𝐷  ∙∈�2 ∙  𝜎𝐷2+ �∈𝐴�2 ∙   𝜎𝐴2 = ∈2 ��𝜎  𝐴𝑈𝐶𝑛𝑒𝑡 𝐴𝑈𝐶𝑛𝑒𝑡�2 + �2𝜎𝐷𝐷 �2 + �𝜎𝐴𝐴 �2� 
The results for standard deviation are shown in the plot below for both detector systems. 
Results, indicates that the uncertainty in the efficiency is around 6%.  
 
Fig. 16, Standard Deviation for both detector systems 
The standard deviation estimates were obtained using: * the net area under curve from 
measurements, * the standard deviation in the net area from Maestro software, * the 
uncertainty in distance between source and detector which was estimated to ±2 cm (at 74 cm), 
* the uncertainty in activity given in the specification for reference sources to 𝜎𝐴/𝐴 =3%. For 
NaI(TI) detector the resulting standard deviation in efficiency is approximately ±0.03, while for 
HPGe it is ±0.02. 
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XI. Distance estimation for the measurements with NaI(TI) detector  
Prior to initiating patient measurements, we wanted to estimate the patient-detector distance 
that would give a similar count rate for activities of 177Lu and 177mLu, and also that would give a 
count rate which yielded a dead time less than 5%. For this reason, distance estimation was 
made by assuming that the photon emission probability can be obtained using the results from 
the determined activity and γ-ray spectroscopy, using the relation:  
  𝑅𝑝𝑒𝑎𝑘 = 𝐴 ∙ 𝑛𝛾 𝑆4𝜋𝐷2 ∙  𝜖  =>      𝑅𝑝𝑒𝑎𝑘𝐴 = 𝑛𝛾 ∙ 𝑆4𝜋𝐷2 ∙ 𝜖  �𝐶𝑃𝑆𝐵𝑞 �   (15) 
Thus, the determination of NaI(TI) detector efficiency for detecting 177Lu at 208 keV, and 177mLu 
at 378 keV and at 418 keV was estimated, using the efficiency values previously obtained from 
reference sources, as shown in Appendix IX. 
 
      Fig. 17, Distance estimation for detector NaI(TI) efficiency activity detection of 177Lu and 177mLu 
Therefore, for the 1st time point the measurement was performed at a longer distance in order 
to obtain a sufficient count rate while keeping the dead time as low as possible (less than 5%), 
while at a later time the measurements were performed at closer distance geometry in order to 
obtain sufficient count rate, so the data analysis could be possibly performed.  
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XII. The Activity determination of a 177Lu sample using the HPGe detector system 
The γ-ray spectra analysis for the determination of the 177Lu /177mLu ratio using HPGe detector 
system has been made and analyzed by APEX software. These measurements were practically 
performed prior to my involvement in the project. For practical purposes and familiarization 
with the energy peak determination by using APEX software a practical experiment has been 
performed by measuring a sample of 177Lu.  A practical examination of how well different peaks 
can be separated and detected by the detector system has been conducted. An illustration of 
the experimental setup is shown in the figure below: 
 
      Fig. 18, HPGe detector system used for measurement of 177Lu sample  
In previous measurement three different samples of 177Lu / 177mLu, consisting of cans of 60ml 
containing well-mixed radionuclide solutions, were placed in a close-detector geometry (2π). 
Different energy peaks were identified using a predefined radionuclide library was used 
(identifying the γ-ray energies, based on abundances, and the half-lives of the radionuclides). 
These measurements were performed on 20110912 and 20110928. 
The HPGe detector energy was well calibrated, and its efficiency had been determined for 
different geometries by earlier measurements. The detailed γ-ray spectrum analysis reports 
have been used as a reference data for further analysis. Using the report information on peak 
identification as well as the data acquisition time, the measurement performed by different 
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detectors (mainly ADC2 and ADC3), were used for the determination of 177Lu/177mLu activities. 
Please note that a detailed summary containing all relevant information on the samples and 
above mentioned parameters are presented in the table under Appendix X. The 177mLu activity 
for each of the energy peaks (keV) for all the samples, was determined. Furthermore, by using 
the information on the decay data for both 177Lu and 177mLu, the γ’s belonging to both 177Lu 
and 177mLu, were quantified by using the information on the energy peaks from the reports on 
gamma ray spectra analysis: 
Energy [keV] Yield % 
105.36 12.34 
112.95 20.44 
128.50 15.50 
153.28 16.90 
174.39 12.61 
204.10 13.80 
208.37 57.0 
228.37 37.00 
281.79 14.10 
327.68 18.10 
413.54 17.40 
418.54 21.30 
           Table 3, Radionuclide library from APEX gamma ray spectra analysis report, valid for 177mLu 
Since both 177Lu and 177mLu have gamma energies at 112.95 keV and 208.37 keV, other gamma-
peaks for 177mLu were used for activity determination. The efficiency was stated to be better 
determined for the higher energy range, and therefore the peaks at 281.79 keV, 327.68 keV and 
418.54 keV, were used. The 177Lu  activity was then determined by subtraction of the 177mLu 
activity and correcting for the different half-lifes. Based on the measurements of one set of 3 
samples, it was found that, in the examined samples, the amount of 177Lu at radionuclide 
production was 0.025% thus in accordance with the values stated by the manufacturer of 177Lu 
of being <0.05%. From the other set of 3 samples the activity determination was not possible 
because the measurements have been performed too late (at 171 days), i.e. when the activity 
of 177Lu was under the detection limit of the detector system.  
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XIII. Patient Measurements 
The methodology for patient measurements has been well defined on a basis of above 
mentioned principles in order to accurately determine the TB Activity.  
In total 7 patients have been part of this study, 3 males and 4 females. After administration 
of 177Lu-Dotatate on day 0, measurement 1 has been performed on day 7. This is the same day 
as the last image is taken for routine dosimetry purposes and is used for comparison with the 
TB activity determined from images. The 2nd and 3rd measurements have been performed when 
the patient return for a doctor visit at approximately 1.5 month, and before start of new 
treatment at approximately 2.5 months after administration. All of the patients have 
undergone at least 2 measurements at different time points. Four patients have undergone a 
3rd measurement. Within this frame, the geometry using NaI(TI) detector system for all of the 
patient measurements was used, while for some of the measurements HPGe was also 
employed for comparison purposes. The HPGe detector system was used for two patients at 1st 
time point, four measurements on the 2nd session and one in the 3rd session. 
Anterior and posterior measurements were performed and a detailed patient protocol on 
measurement has been maintained. The distance for patient measurement has been made to  
the center of the body and has varied for the different measurements. Generally, the patient-
detector distance for the 1st time point measurement was approximately 2.90m-3.40m, giving a 
detector dead time of less than 5%. For later measurement time points the patient was 
positioned closer to the detector system, in order to obtain a sufficient count rate and keep the 
measurement time reasonably low (10min per view, in total 20min). The distance was 
approximately 1.20m-3.10m, respectively for the last measurement (3rd measurement) 1.51m-
1.33m. Prior to every measurement, the background was measured at an appropriate time 
length at   40 000 s.  The energy calibration for NaI(TI) detector was made using 57Co and 137Cs, 
while 133Ba was used for verification purposes of the calibration stability, which showed slight 
variations in the energy scale. For this purpose, a manual energy calibration was also performed 
by a linear fitting of the channel versus γ energy data.  A picture illustrating an anterior patient 
measurement is shown below: 
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                             Fig. 19,  An illustration from Patient measurement session 
The data acquisitions in Maestro were converted into the Excel program for further analysis. 
The CPS was determined as the number of counts divided by the live time of the detector 
measurement. The background subtraction was also performed, as illustrated from the patient 
2 in anterior measurement, is shown in the plots below: 
a) Patient Measurement – An example from Patient no.2 in anterior position using NaI(Tl) 
detector system, 1st measurement, 7 days after the administration date: 
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b) Patient Measurement – An example from Patient no.2 in anterior position using NaI(Tl) 
detector system, 2nd measurement, 41 days after the administration date:  
           
 
 
c) Patient Measurement – An example from Patient no.2 in anterior position using NaI(Tl) 
detector system, 3rd  measurement, 70 days from the date of administration: 
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Fig. 20, Data analysis from patient measurements, example from patient number 2, anterior 
measurements:        
For further analysis of data, a plot was obtained in order to identify the channel # in the 
spectrum. The background CPS was subtracted from the Patient CPS. The energy window was 
determined for the 208 photo-peak in order to obtain the Gross Area CPS (as a sum of the CPS 
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in the energy window), and the net area CPS (Rpeak) was determined by subtraction of the 
scatter area, as described above. Furthermore, for purposes of stability-check of the detector 
system and of the results calculated by Maestro software, a determination was also made of: 
 Total count rate in background in energy windows at 208 keV peak 
 Sum of background CPS in energy window 
 Total background count rate per channel# in the energy window at 208 keV  
Total count rate in background in energy windows 208 keV peak - Number of channels for 208 
keV peak 
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XIV. Applied Methods for TB Activity determination on Patients 
For the measured data on Rpeak the activity in the Patient TB was determined in Excel. The 
assumption was made that point source geometry could be applied. However, since the activity 
was located at an unknown depth in tissue, correction for photon attenuation in the patient 
body was also applied. Attenuation correction using the conjugate view method is described 
below.  
If the activity had been only 177Lu, then the detector measurements in the anterior view (the 
detector placed in front of the patient), the detected net count rate due to 208 keV photons 
was: 
                                            𝑅𝑝𝑒𝑎𝑘,𝑎𝑛𝑡 = 𝐴𝑇𝐵 ∙ 𝑛𝛾 ∙ 𝑆4𝜋𝐷𝑎𝑛𝑡2 ∙ 𝜖 ∙  𝑒−𝜇𝑥       (16) 
where x is the depth of the activity source in the patient in the direction from the front. Here 𝑛𝛾 
is the number of emitted 208 keV gammas per decay of 177Lu, 𝜖 is the detector photopeak 
efficiency valid for 208 keV photons. Dant is the distance from the detector surface to the patient 
mid-point in the anterior-posterior direction, µ is the linear attenuation coefficient valid for 208 
keV, and other terms are as given in the previous sections. Then in the posterior view (the 
detector placed behind the patient’s back): 
   𝑅𝑝𝑒𝑎𝑘,𝑝𝑜𝑠𝑡 = 𝐴𝑇𝐵 ∙ 𝑛𝛾 ∙ 𝑆4𝜋𝐷𝑝𝑜𝑠𝑡2 ∙ 𝜖 ∙  𝑒−𝜇(𝑇−𝑥)        (17) 
where T is the total patient thickness, and Dpost is the distance to the patient midpoint as 
measured from the back. By applying the geometric mean for both anterior and posterior 
views:[43] 
�𝑅𝑝𝑒𝑎𝑘,𝑎𝑛𝑡 ∙  𝑅𝑝𝑒𝑎𝑘,𝑝𝑜𝑠𝑡 = �𝐴𝑇𝐵 ∙ 𝑛𝛾 ∙  𝑆4𝜋𝐷𝑎𝑛𝑡2 ∙ 𝜖 ∙  𝑒−𝜇𝑥∙ ∙ 𝐴𝑇𝐵 ∙ 𝑛𝛾 ∙ 𝑆4𝜋𝐷𝑝𝑜𝑠𝑡2 ∙ 𝜖 ∙  𝑒−𝜇(𝑇−𝑥) =
𝐴𝑇𝐵 ∙ 𝑛𝛾 ∙ 𝜖 ∙ 𝑆 ∙  14𝜋𝐷𝑎𝑛𝑡𝐷𝑝𝑜𝑠𝑡 ∙ √𝑒−𝜇𝑇∙            (18) 
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The TB Activity could be determined using the equation: [43] 
𝐴𝑇𝐵 = �𝑅𝑝𝑒𝑎𝑘,𝑎𝑛𝑡 ∙  𝑅𝑝𝑒𝑎𝑘,𝑝𝑜𝑠𝑡 ∙ 4𝜋𝐷𝑎𝑛𝑑𝐷𝑝𝑜𝑠𝑡𝑛𝛾∙𝜖∙𝑆  ∙ 1�𝑒−𝜇𝑇∙ = �𝑅𝑝𝑒𝑎𝑘,𝑎𝑛𝑡 ∙  𝑅𝑝𝑒𝑎𝑘,𝑝𝑜𝑠𝑡 ∙ 4𝜋𝐷𝑎𝑛𝑑𝐷𝑝𝑜𝑠𝑡𝑛𝛾∙𝜖∙𝑆  ∙  √𝑒𝜇𝑇∙               (19) 
Here the only term that is specific for a particular radionuclide is 𝑛𝛾, while other terms relate to 
the measurement geometry, detector or the photon energy 208 keV. To take the different 
sources of 208 keV photon emissions into account (177Lu1, 177mLu and 177Lu2), the calculation of 
the activity has been made in different steps: 
First the measured values of Rpeak were corrected for the distance (D), the photo-peak 
efficiency (ϵ) and the detector surface (S). This gave a value Rcorr,ant:[43] 
    𝑅𝑐𝑜𝑟𝑟,𝑎𝑛𝑡 = 𝑅𝑝𝑒𝑎𝑘,𝑎𝑛𝑡  ∙  4𝜋 𝐷𝑎𝑛𝑡2𝜖 ∙𝑆        (20) 
And the corresponding calculation to obtain Rcorr,post. Then attenuation correction was made. 
The patient thickness (cm) was measured in CT images, in transaxial slices over the kidney-liver 
area. For this purpose, the Xeleris imaging station was used, and measurement using a caliper 
in the images. The linear attenuation coefficient for 208 keV was determined from reference 
values (NIST). An attenuation-corrected count rate was obtained as: [43]  
   𝑅𝑎𝑡𝑡−𝑐𝑜𝑟𝑟 = �𝑅𝑐𝑜𝑟𝑟,𝑎𝑛𝑡 ∙ 𝑅𝑐𝑜𝑟𝑟,𝑝𝑜𝑠𝑡  ∙  √𝑒𝜇𝑇        (21) 
From the detected count-rate we wanted to determine the activities from the different sources 
(177Lu1, 177mLu and 177Lu2). In order to determine the count rate from the different sources of 
208 keV gammas, a theoretical relationship was applied, as supplied by supervisors (Appendix 
V). A basic assumption in this relationship was that the radionuclide purity was known, meaning 
the amount of the radioactive solution that is 177Lu at the time of production. Since the 
producer states that <0.05% of the total activity is in the form of 177mLu, we have assumed 
0.05% as a worst case scenario.  
From the theoretical relationship (depicted in the figures 11 and 12 in section VIII) an 
expression for the rate of photon emission at measurement time (tm) is obtained:  [43] 
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𝑁208,𝑇𝑜𝑡(𝑡𝑚) = 𝑁177𝑚𝐿𝑢(𝑡𝑚) + 𝑁177𝐿𝑢1(𝑡𝑚) + 𝑁177𝐿𝑢2(𝑡𝑚) = 𝑁208,𝑇𝑜𝑡(𝑡𝑚) ∙ �𝑁177𝑚𝐿𝑢(𝑡𝑚)𝑁208,𝑇𝑜𝑡(𝑡𝑚)� +
𝑁208,𝑇𝑜𝑡(𝑡𝑚) ∙ �𝑁177𝐿𝑢1(𝑡𝑚)𝑁208,𝑇𝑜𝑡(𝑡𝑚)� +  𝑁208,𝑇𝑜𝑡(𝑡𝑚) ∙ �𝑁177𝐿𝑢2(𝑡𝑚)𝑁208,𝑇𝑜𝑡(𝑡𝑚)� = 𝑁208,𝑇𝑜𝑡(𝑡𝑚)  ∙  𝐹177𝑚𝐿𝑢(𝑡) +
𝑁208,𝑇𝑜𝑡(𝑡𝑚)  ∙  𝐹177𝐿𝑢1(𝑡) + 𝑁208,𝑇𝑜𝑡(𝑡𝑚)  ∙  𝐹177𝐿𝑢2(𝑡)                                                        (22) 
In Appendix V, derivations are given of fractions F(t), of the respective term of the 208 keV 
photon-emission rate, in relation to the total 208 keV photon-emission rate. Using these 
fractions, the TB activity of the different radionuclides was then determined as: [43] 
                              𝐴177𝐿𝑢1,𝑇𝐵 = 𝑅𝑎𝑡𝑡−𝑐𝑜𝑟𝑟  ∙  𝐹177𝐿𝑢1(𝑡)/𝑛𝛾,208,177𝐿𝑢  
                             𝐴177𝑚𝐿𝑢,𝑇𝐵 = 𝑅𝑎𝑡𝑡−𝑐𝑜𝑟𝑟  ∙  𝐹177𝑚𝐿𝑢(𝑡)/𝑛𝛾,208,177𝑚𝐿𝑢  
                            𝐴177𝐿𝑢2,𝑇𝐵 = 𝑅𝑎𝑡𝑡−𝑐𝑜𝑟𝑟  ∙  𝐹177𝐿𝑢2(𝑡)/𝑛𝛾,208,177𝐿𝑢                               (23) 
The values on TB Activity have been compared with the results obtained from dosimetric 
images using gamma camera. 
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XV. Absorbed Dose Calculation in Organs 
From the measurement using the NaI(Tl) and HPGe detector systems, it is only the TB activity 
that can be determined. In order to make dosimetric calculations in organs, some further 
assumptions are necessary. For this purpose, the image-based estimates of the activity were 
taken as baseline. From the images taken on last day (on day 7) a comparison was made of the 
TB activity determined from the detector measurements and the images to assure a good 
correspondence. At this time (day 7) the main radionuclide component is still 177Lu as can be 
seen in figure 10. Therefore, based on the images, the fraction of TB activity located at different 
organs was determined, for liver, spleen, kidneys and remainder of body (which is the TB 
activity minus the activity in the other organs). The detector measurements at the late time 
point (approximately 1.5 month) were then analyzed by the assumption that distribution within 
the patient body was the same as on day 7. This means that from the images a fractional 
activity was determined as:  [43] 
  𝐹𝐴𝑜𝑟𝑔𝑎𝑛(𝑑𝑎𝑦7) = 𝐴𝑜𝑟𝑔𝑎𝑛(𝑑𝑎𝑦7)/ 𝐴𝑇𝐵(𝑑𝑎𝑦7) only 177Lu    (24) 
Then, the activity in an organ at the late time point was determined from the detector 
measurements as: 
𝐴𝑜𝑟𝑔𝑎𝑛(𝑑𝑒𝑡𝑒𝑐𝑡𝑜𝑟 @ 𝑙𝑎𝑡𝑒 𝑡𝑖𝑚𝑒 𝑝𝑜𝑖𝑛𝑡) = 𝐹𝐴𝑜𝑟𝑔𝑎𝑛(𝑑𝑎𝑦7) ∗  𝐴𝑇𝐵(𝑑𝑒𝑡𝑒𝑐𝑡𝑜𝑟 @ 𝑙𝑎𝑡𝑒 𝑡𝑖𝑚𝑒 𝑝𝑜𝑖𝑛𝑡)   
                                                                                                                                                                  (25) 
This last analysis was made with regard to the different amounts of the source components 
(177Lu1, 177mLu and 177Lu2) at different times after radionuclide production. In effect, the 
analysis was made: [43] 
𝐴177𝐿𝑢1,𝑜𝑟𝑔𝑎𝑛(@ 𝑙𝑎𝑡𝑒 𝑡𝑖𝑚𝑒) = 𝐴177𝐿𝑢1,𝑇𝐵 ∗  𝐹𝐴𝑜𝑟𝑔𝑎𝑛(𝑑𝑎𝑦7) =  𝑅𝑎𝑡𝑡−𝑐𝑜𝑟𝑟(@ 𝑙𝑎𝑡𝑒 𝑡𝑖𝑚𝑒 ) ∗ 𝐹177𝐿𝑢1(@ 𝑙𝑎𝑡𝑒 𝑡𝑖𝑚𝑒)/𝑛𝛾,208,177𝐿𝑢 ∗  𝐹𝐴𝑜𝑟𝑔𝑎𝑛(𝑑𝑎𝑦7)           
𝐴177𝑚𝐿𝑢,𝑜𝑟𝑔𝑎𝑛(@ 𝑙𝑎𝑡𝑒 𝑡𝑖𝑚𝑒) = 𝐴177𝑚𝐿𝑢,𝑇𝐵 ∗  𝐹𝐴𝑜𝑟𝑔𝑎𝑛(𝑑𝑎𝑦7) =  𝑅𝑎𝑡𝑡−𝑐𝑜𝑟𝑟(@ 𝑙𝑎𝑡𝑒 𝑡𝑖𝑚𝑒 ) ∗ 𝐹177𝑚𝐿𝑢(@ 𝑙𝑎𝑡𝑒 𝑡𝑖𝑚𝑒)/𝑛𝛾,208,177𝑚𝐿𝑢 ∗  𝐹𝐴𝑜𝑟𝑔𝑎𝑛(𝑑𝑎𝑦7)                                      (26) 
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𝐴177𝐿𝑢2,𝑜𝑟𝑔𝑎𝑛(@ 𝑙𝑎𝑡𝑒 𝑡𝑖𝑚𝑒) = 𝐴177𝐿𝑢2,𝑇𝐵 ∗  𝐹𝐴𝑜𝑟𝑔𝑎𝑛(𝑑𝑎𝑦7) =  𝑅𝑎𝑡𝑡−𝑐𝑜𝑟𝑟(@ 𝑙𝑎𝑡𝑒 𝑡𝑖𝑚𝑒 ) ∗ 𝐹177𝐿𝑢2(@ 𝑙𝑎𝑡𝑒 𝑡𝑖𝑚𝑒)/𝑛𝛾,208,177𝐿𝑢 ∗  𝐹𝐴𝑜𝑟𝑔𝑎𝑛(𝑑𝑎𝑦7)      (27) 
Dosimetry was then performed in the OLINDA dosimetry software. Different sets of data were 
analyzed for this purpose.  
“Set 1”: Input to OLINDA was the activity data for each organ, at the imaging times 
(approximately 0.5h, 24h, 96h (day4) and168h (day7), only 177Lu. This represents the data set 
that is included as part of routine dosimetry in the clinic. 
“Set 2”: Input to OLINDA was in addition to Set 1, the activities determined from the detector 
measurements i.e. 𝐴𝑜𝑟𝑔𝑎𝑛(@ 𝑙𝑎𝑡𝑒 𝑡𝑖𝑚𝑒). This was then separated into different components, 
as described above, because OLINDA has different DFs for 177Lu and 177mLu. 
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XVI. Results  
As already mentioned part of the study was in total 7 patients, 4 female and 3 male. Anterior 
and Posterior measurements were performed for each patient, excluding patient no.1 who was 
only measured in anterior position. The data analysis performed for both positions were further 
used for determination of TB activity for each patient. In order to determine the Activity of 
different contributing components, the R (net area under the curve) was determined for the 
measurements in anterior and posterior,  and it was corrected for distance, detector surface, 
efficiency (cps) for both measurement positions, and with this value the determination of the 
geometric mean has been determined. The mass attenuation coefficient µ/ρ for 208 keV 
photons in soft tissue was used based on the ICRP-44, estimated to be 0.134 g/cm2  and ρ =1 
g/cm3. By also knowing the patient thickness the attenuation correction value was determined 
as √𝑒𝜇𝑇. The activity values determined from image based (Planar and SPECT), were used in 
combination with those measured from the detector systems. Furthermore, the activity in 
different organs was also determined, mainly kidneys, liver and spleen, while the remainder 
activity is assumed to be evenly distributed. The Activity of each organ was divided into the 
activity of particular contributing components 177Lu1+177Lu2 and 177mLu as a percent injected 
dose (%ID), to be used for further determination of the absorbed dose to each organ. The 
absorbed dose was estimated using the DFs (dose factors), from OLINDA software. A 
combination of several methods for determination of the activity in the total body and different 
organs, especially to the kidneys (considered to be the main organ at risk) was applied. Thus, 
this implies the method from Image base method, Planar and SPECT (%ID) for different time 
points, referred to as “Case 1”, 177Lu1+177Lu2 referred to as “Case 2a” and only 177mLu “Case 2b” 
Furthermore the 177Lu1 activity, 177mLu  and 177Lu2 contribution at different time points has 
been estimated. 
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Because of the fact, that patient measurements were performed at different time points, the 
outcomes show different values for the activities. Furthermore, the radionuclide purity is an 
important factor for a safe administration of the radiotherapy in Patients treated with 177Lu.-
DOTATATE. In the following tables, details on patient included in the research project, their 
gender, administered activity and date of administration, therapy cycle as well as the details 
related to their weight and thickness are presented. Moreover, the TB corrected count rate 
from anterior and posterior measurement, and detector systems used, are listed in the 
following table: 
Patient Initials Gender Cycle 
no 
Administration date  
[MBq] 
Administered 
Activity [MBq] 
Weight 
[kg] 
Thickness 
[cm] 
1 AA F 4 4/19/2012 7435 57.4 18.8 
2 TA M 2 4/26/2012 7480 65 21.9 
3 CK M 1 5/31/2012 7235 99.8 27.4 
4 MC F 4 5/31/2012 7145 60.8 19.1 
5 UH M 4 6/7/2012 7460 77.3 24.3 
5 UH M 5 8/16/2012 7395 74 24.3 
6 SG F 2 6/14/2012 7545 70 20 
7 IN F 6 6/14/2012 7435 61.3 22.7 
                 
TB Corrected Count Rate 
 Measurement 1 
Rcorr, ant-upper; post-lower 
Measurement 2 
Rcorr, ant-upper; post-lower 
Measurement 3 
Rcorr, ant-upper; post-lower 
P NaI(Tl) HPGe Distance NaI(Tl) HPGe Distance NaI(Tl) HPGe Distance 
1 187.69  340 N/A N/A 310    
N/A   N/A N/A 290    
2 276.62  321 3.74  121 0.26 0.07 151 
246.34  308 3.15  121 0.33 0.16 151 
3 147.56  310 1.67 1.26 143 N/A  89 
125.19  300 1.63 1.75 138 N/A  100 
4 107.12  300 1.62 1.31 165    
73.49  298 0.87 0.81 165    
5 113.83  310 1.74 1.28 173    
79.28  300 1.11 1.52 173    
5          
 0.14 15       
6 100.30 86.32 310 0.07  120 N/A   
101.42 85.97 290 0.23  124 N/A   
7 235.09 194.17 310 0.15  125    
 205.53 174.87 290 0.25  120    
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Table no. 4 Details on measured Patient measurements and obtained corrected count rate from TB 
measurements with detector systems 
 
In more details this chapter of the report will address the outcomes from the TB Activity and 
Kidney Activity determination for each of the measured Patient. 
 
PATIENT 1  
The 1st measurement has been performed 7 days after the 4th radiotherapy administration with 
the activity of 7435 MBq. The first measurement was only performed in anterior position at 
distance 340 cm from the center of body using NaI(TI) detector system. The data acquisition 
time was set 305.2 s.  
The 2nd measurement was performed using both detector systems at a distance 310 cm anterior 
and 290 cm posterior from the center of body to the detector systems. The data acquisition 
time for both detectors was 299 s. Unfortunately in this specific case the data could not be 
analyzed and the activity determination at this time point was not possible, because ROI was 
difficult to be identified. 
The data analysis showed that the Activity in the TB after 7 days period, based on the image 
based method was 727.8 MBq after 165.2 hours, while based on NaI(Tl) detector system 
measurement it turned out to be 680.7 MBq (for both contributing terms 177Lu1 and 177Lu2). The 
Activity for each contributing term: 177Lu1, 177mLu, 177Lu2 and 177Lu1+ 177Lu2, is shown in the 
table below: 
TOTAL BODY ACTIVITY (MBq) 
Image based Time p.i. [h] 177Lu1 177mLu 177Lu2 177Lu1 + 177Lu2 
 
0.2 7411.5 4.5 0.16 7411.7 
20.8 2369 1.6 0.08 2369 
92.7 1265.7 1.1 0.10 1265.8 
165.2 727.8 0.9 0.11 728 
NaI(Tl) based 
 165.0 680.7 0.8 0.10 680.8 
Table no. 5 Total Body Activity Image based and NaI(Tl) based at different time points for all 
contributing terms – Patient 1 
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The activity distribution at different time points is shown in the plot below: 
 
 
Fig.  21,  Plot of results from TB activity and Kidney in Patient 1  
The Activity for organs: Kidneys, Liver and Spleen at different time points is shown in the 
following table: 
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Case 1: Planar and SPECT (%ID) 
Time p.i. [h] REMAINDER KIDNEYS LIVER SPLEEN 
 
0.2 86.5 2.5 10 1 
20.8 16.6 1.5 12.8 1.2 
92.7 8.6 0.6 7.3 0.6 
 165.2 4.8 0.3 4.4 0.4 
Case 2a: 177Lu1+177Lu2 
Time p.i. [h] REMAINDER KIDNEYS LIVER SPLEEN 
 
0.2 86.5 2.5 10 1 
20.8 16.6 1.5 12.8 1.2 
92.7 8.6 0.6 7.2 0.6 
165.2 4.8 0.3 4.3 0.4 
Case 2b: 177mLu 
Time p.i. [h] REMAINDER KIDNEYS LIVER SPLEEN 
 
0.283 86.5 2.5 10 1 
20.867 18 1.6 13.9 1.2 
92.733 12.5 0.1 10.6 0.9 
165.25 9.5 0.6 8.5 0.7 
Table no.6, ID% and Absorbed Dose for Kidneys and TB from: Case1: Planar and SPECT, 
Case2a: 177Lu1+177Lu2 and Case 2b: 177mLu for Patient 1 
 
In this particular case, the absorbed dose was not determined, because of the fact that the 1st 
measurement was only performed in anterior position, and the curve fitting in OLIDA was not 
easy way to observe. Meanwhile the data obtained from the 2nd measurement could not be 
analyzed. 
 
PATIENT 2  
The 1st measurement has been performed 7 days after the 2nd radiotherapy administration with 
the activity of 7480 MBq. The first measurement was performed both in anterior and posterior 
position, using NaI(TI) detector at a distance from the center of body 321 cm, respectively 308 
cm for the later measurement. The data acquisition time was 303.5 s (anterior) and 292.3 s 
(posterior). 
The 2nd measurement was performed using only one detector system same as in the 1st 
measurement. Anterior and posterior data acquisition was obtained at 298 s and 298.4 s for the 
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later position of measurement. The distance from the center of body to the detector system 
was 121 cm for both sides of the measurements. 
The 3rd measurement was performed after 70 days from the date of administration using both 
detector systems at a distance 151 cm from the center of body to the detector systems in both 
sides of the measurements. The data acquisition time for NaI(TI) detector was 299.5 s for 
anterior and 299.5 s for posterior, while for HPGe detector it was 299.3 s for anterior and 299.2 
s for posterior measurement. 
Data analysis shows that the Activity in the TB after 7 days period, based on the image based 
method was 1216.1 MBq (after 165.4 hours), while based on NaI(Tl) detector system 
measurement it showed to be 1128.3 MBq (after 166 hours). In this particular patient the 
measurement was also performed at a later time point, more specifically after 61 days 
(approximately, 2 month after the administration). The activity shows to be 0.5 MBq for NaI(Tl) 
based method and 0.2 MBq for HPGe based method. In the following table the activity at 
different time points for used methods as well as the activity for each contributing terms, is 
shown: 
TOTAL BODY ACTIVITY [MBq] 
Image based Time p.i. [h] 177Lu1 177mLu 177Lu2 177Lu1 + 177Lu2 
 
0.3 7456 4.5 0.18 7456.2 
22.4 3660.8 2.4 0.13 3661 
93.3 2005.3 1.8 0.17 2005.4 
165.4 1216.1 1.4 0.19 1216.3 
NaI(Tl) based 
 
166.0 1128.3 1.3 0.17 1128.5 
958.7 12.8 0.4 0.09 12.9 
1462.0 0.6 0.1 0.03 0.6 
HPGe based  
 1462.0 0.2 0.05 0.01 0.2 
 
Table no. 7 Total Body Activity Image based and NaI(Tl) based at different time points for all 
contributing terms – Patient 2 
 
Furthermore, the activity distribution at different time points is shown in the plot below: 
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Fig 22,  Plots on results from Patient 2 measurements at different time points, TB Activity and Kidneys 
The data analysis shows that the TB Activity after 7 days period of time still remains high 
(comparing to other patient measurements), it results to be 1216.1 MBq (based on planar and 
SPECT), 1128.3 MBq from NaI(Tl) based measurement. The 2nd measurement was conducted 
after approximately 39 days and the activity results to be 12.8 MBq. This was the only patient 
which after the 3rd measurement the data analysis could still be performed. It was carried out 
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after approximately 61 days (from the date of administration) and from data analysis the 
Activity results to be: for NaI(TI) based  0.5 MBq and 0.2 MBq for the HPGe based method.  
Furthermore the determination of the absorbed dose was calculated by fitting the activity data 
to a function for each particular organ, using OLINDA software. The absorbed dose 
determination for each organ was made in the unit of Gy. Below is shown the %ID, which is the 
activity in and organ, divided by the injected amount, in percent. 
 In the following table the activity concentration for each particular organ is shown:  
Case 1: Planar and SPECT  
 
 
ABSORBED DOSE [Gy] 
Case 1 
Time p.i. [h] REMAINDER KIDNEYS LIVER SPLEEN 
 
0.3 89.4 2.2 6.5 1.9 
22.4 36 2 7.9 3.2 
93.3 18.6 1 5.4 1.9 Kidneys Total Body 
165.4 11.4 0.4 3.5 0.9 5.3 0.7 
Case 2a: 177Lu1+177Lu2  
 
 
 
 
ABSORBED DOSE [Gy] 
Case 2a + 2b 
Time p.i. [h] REMAINDER KIDNEYS LIVER SPLEEN 
 
 
 
 
 
0.3 89.4 2.2 6.5 1.9 
22.4 36 2 7.9 3.2 
93.3 18.6 1 5.4 1.9 
165.4 11.4 0.4 3.5 0.9 
958.7 0.1 0.00 0.03 0.01  Kidneys Total Body 
1462.0 0.00 0.00 0.00 0.00  5.6 0.8 
Case 2b: 177mLu 
Time p.i. [h] REMAINDER KIDNEYS LIVER SPLEEN 
 
0.3 89.5 2.2 6.5 1.9 
22.4 39.5 2.1 8.7 3.5 
93.3 27.2 1.4 7.9 2.8 
165.4 22.4 0.9 6.9 1.9 
958.7 6.6 0.2 2.03 0.6  
1462.0 2.2 0.1 0.7 0.2  
Table no.8, ID% and Absorbed Dose for Kidneys and TB from: Case1: Planar and SPECT, 
Case2a: 177Lu1+177Lu2 and Case 2b: 177mLu for Patient 2 
 
Therefore, the absorbed dose based on the Planar and SPECT method, for the kidneys is 5.3 Gy 
and for the TB, 0.75 Gy. The method based on the images and NaI(Tl) based measurements the 
absorbed dose results to be for the kidneys 5.6 Gy and for the total body 0.8 Gy. 
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PATIENT 3 
The 1st measurement has been performed 7 days after the 1st radiotherapy administration with 
the activity of 7235 MBq. The measurement has been performed in both anterior and posterior 
position, at a distance 310 cm, respectively 300 cm for the later measurement. The data 
acquisition time was 290.3 s (anterior) and 290.2 s posterior. 
The 2nd  measurement was performed using both detector systems, NaI(TI) and HPGe. Anterior 
and posterior data acquisition were obtained at 299.04 s (anterior) and 298.98 s (posterior) for 
measurements performed with NaI(TI), while the data acquisition using HPGe detector was 
298.6 s (anterior) and 298.5 s (posterior). The distance from the center of body to the detector 
system was 143 cm for the anterior measurement and 138 cm for the posterior measurement 
for both detector systems.  
The 3rd measurement was performed using NaITI) detector system only. The distance from the 
center of body was set to be 89 cm for anterior measurement and 100 cm for posterior 
measurement. The decision for having shorter distance was made due to the fact that we could 
obtain the desirable number of counts registered. In this measurement the data acquisition 
time was set longer at 679.4 s for anterior measurement and 630.7 s for posterior 
measurement. For this particular measurement the data could not be analyzed. From data 
analysis the TB Activity after 7 days, according to the image based method the activity is 879.1 
MBq (after 164.4 h), while based on the NaI(Tl) measurement it resulted to be only 873 MBq . 
The activity for each contributing terms and different time points measurements are shown in 
the following table: 
TOTAL BODY ACTIVITY [MBq] 
Image based Time p.i. [h] 177Lu1 177mLu 177Lu2 177Lu1 + 177Lu2 
 
0.2 7214 4 0.08 7214 
23.3 2624.5 1.6 0.06 2624.5 
92.3 1434.6 1.2 0.10 1434.7 
164.4 879.2 0.9 0.11 879.3 
NaI(Tl) based 
 
165.1 873 0.9 0.11 873.2 
957.5 9 0.2 0.06 9.1 
HPGe based 
 957.49 3.2 0.08 0.02 3.2 
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Table no. 9 Total Body Activity Image based, NaI(Tl) and HPGe based respectively, at different time 
points for all contributing terms – Patient 3 
 
The TB activity at different time points is shown in the plot below: 
 
 
Fig. 23, Plot on results from TB activity  and Kidneys in Patient 3 
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The data analysis on Activity determination in the TB after the 7th day of the radiotherapy 
administration results to be 879.2 MBq. As the 2nd measurement was performed after 
approximately 40 days, the activity results to be for NaI(TI) detector 9 MBq while the results 
from measurements performed with HPGe detector on data analysis for activity determination 
results to be 3.1 MBq.  The 3rd measurement was performed after 52 days (from the date of 
administration). In this particular measurement, even though a longer acquisition time was set, 
it was not possible to mark the ROI therefore, no activity calculation was possible. It was mainly 
background interference.  
Furthermore the determination of the absorbed dose was calculated by fitting the activity data 
to a function for each particular organ, using OLINDA software. The absorbed dose 
determination for each organ was made in the unit of Gy. Below is shown the %ID, which is the 
activity in and organ, divided by the injected amount, in percent. 
Case 1: Planar and SPECT  
 
ABSORBED DOSE [Gy] 
Case 1 
Time p.i. [h] REMAINDER KIDNEYS LIVER SPLEEN 
 
0.2 89.7 1.6 8 0.7 
23.3 23.7 1.4 10.2 1 
92.3 12.3 0.5 6.6 0.4 Kidneys Total Body 
164.4 7.4 0.3 4.4 0.2 2.9 0.5 
Case 2a: 177Lu1+177Lu2  
 
 
 
 
ABSORBED DOSE [Gy] 
Case 2a+2b 
Time p.i. [h] REMAINDER KIDNEYS LIVER SPLEEN 
 
 
 
 
 
0.2 89.7 1.6 8 0.7 
23.3 23.7 1.4 10.2 1 
92.3 12.3 0.5 6.6 0.4 
164.4 7.3 0.2 4.4 0.2 
957.5 0.07 0.00 0.04 0.00  Kidneys Total Body 
Case 2b: 177mLu 
3.1 0.6 
Time p.i. [h] REMAINDER KIDNEYS LIVER SPLEEN 
 
0.2 89.7 1.6 8 0.7 
23.3 26.1 1.5 11.3 1 
92.3 18 0.7 9.6 0.7 
164.4 14.4 0.4 8.7 0.4 
957.5 3.9 0.09 2.3 0.1  
Table no.10, ID% and Absorbed Dose for Kidneys and TB from: Case1: Planar and SPECT, 
Case2a: 177Lu1+177Lu2 and Case 2b: 177mLu for Patient 3 
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Therefore, the absorbed dose based on the Planar and SPECT method, for the kidneys is 2.9 Gy 
and for the TB, 0. 5 Gy. The method based on the images and NaI(Tl) based measurements the 
absorbed dose results to be for the kidneys 3.1 Gy and for the total body 0.6 Gy. 
 
PATIENT 4 
The 1st measurement was performed 7 days after the 4th cycle radiotherapy administration with 
the activity of 7145 MBq. The measurement was performed both in anterior and posterior 
position, at a distance 310 cm, respectively 298 cm for the later measurement. The data 
acquisition time was 293.9 s (for anterior measurement) and 293 s (for posterior 
measurement). 
The 2nd measurement was performed using both detector systems, NaI(TI) and HPGe. Anterior 
and posterior data acquisition was obtained at 299.3 s (anterior) and 299.4 s (posterior) for 
measurements performed with NaI(TI), while the data acquisition using HPGe detector was 299 
s (anterior) and 299.2 s (posterior). The distance from the center of body to the detector 
system was 165 cm, from both detector systems. The data analysis showed that the Activity in 
the TB after 7 days period, based on the image based method was 334.1 MBq (after 165 hours), 
while based on NaI(Tl) method it shows to be 307.7 MBq. At a later time point approximately 
after 32 days, the total body activity for the measurement with NaI(Tl) showed to be 4 MBq 
while for HPGe, 3.44 MBq.  
TOTAL BODY ACTIVITY [MBq] 
Image based Time p.i. [h] 177Lu1 177mLu 177Lu2 177Lu1 + 177Lu2 
 
0.6 7124.2 4 0.08 7124.3 
20.5 1259.8 0.7 0.02 1259.8 
92.9 605.2 0.5 0.04 605.2 
165.0 334.1 0.4 0.04 334 
NaI(Tl) based 
 
165.6 307.7 0.3 0.04 307.8 
790.5 4 0.06 0.01 4 
HPGe based 
 790.55 3.4 0.05 0.01 3.4 
Table no. 11 Total Body Activity Image based and NaI(Tl) based at different time points for all 
contributing terms   
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Furthermore, the activity distribution at different time points is shown in the plot below: 
 
 
Fig.  24. Plot on results from TB activity  and Kidneys in Patient 4  
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determination for each organ was made in the unit of Gy. Below is shown the %ID, which is the 
activity in and organ, divided by the injected amount, in percent. 
 
Case 1: Planar and SPECT 
 
 
ABSORBED DOSE [Gy] 
Case 1 
Time p.i. [h] REMAINDER KIDNEYS LIVER SPLEEN 
 
0.6 92.9 2.7 3.4 1 
20.5 12 1.7 2.9 1 
92.9 5.8 0.7 1.4 0.5 Kidneys Total Body 
165.0 3.3 0.3 0.8 0.3 4.2 0.3 
Case 2a: 177Lu1+177Lu2  
 
 
 
 
ABSORBED DOSE [Gy] 
Case 2a+2b 
Time p.i. [h] REMAINDER KIDNEYS LIVER SPLEEN 
 
 
 
 
 
0.6 92.9 2.7 3.4 1 
20.5 12 1.7 2.9 1 
92.9 5.8 0.7 1.3 0.5 
165.0 3.3 0.3 0.8 0.3 
790.5 0.04 0.00 0.01 0.00  Kidneys Total Body 
Case 2b: 177mLu 
4.5 0.3 
Time p.i. [h] REMAINDER KIDNEYS LIVER SPLEEN 
 
0.6 93.1 2.7 3.4 1 
20.5 13.1 1.8 3.1 1.2 
92.9 8.6 1 2 0.8 
165.0 6.4 0.7 1.6 0.6 
790.5 1.08 0.1 0.3 0.1  
Table no.12, ID% and Absorbed Dose for Kidneys and TB from: Case1: Planar and SPECT, 
Case2a: 177Lu1+177Lu2 and Case 2b: 177mLu for Patient 4 
 
Therefore, the absorbed dose based on the Planar and SPECT method, for the kidneys is 4.2 Gy 
and for the TB, 0. 3 Gy. The method based on the images and NaI(Tl) based measurements the 
absorbed dose results to be for the kidneys 4.5 Gy and for the total body 0.3 Gy. 
 
PATIENT 5 
The 1st measurement was performed 7 days after the 4th cycle of radiotherapy administration 
with the activity of 7460 MBq. The first measurement was performed only with NaI(TI) detector 
at a distance of 310 cm for anterior measurement and 300 cm for posterior measurement. The 
data acquisition time was 292.8 s (for anterior measurement) and 293.8 s (for posterior 
measurement). 
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The 2nd measurement was performed using both detector systems, NaI(TI) and HPGe. Anterior 
and posterior data acquisition was obtained for 299.2 s (anterior) and 299.1 s (posterior) for 
measurements performed with NaI(TI), while the data acquisition using HPGe detector was 
298.9 s (anterior) and 298.74 s (posterior). The distance from the center of body to the detector 
systems was 173 cm from both detector systems.  
The data analysis showed that the Activity in the TB after 7 days period, based on the image 
based method was 514.2 MBq (after 166 hours), while for NaI(T) based method it showed to be 
482.1 MBq. At a later time point approximately after 35 days the total body activity for both 
NaI(Tl) and HPGe based methods resulted to be 6.4 MBq.  
TOTAL BODY ACTIVITY 
Image based Time p.i. [h] 177Lu1 177mLu 177Lu2 177Lu1 + 177Lu2 
 
0.2 7434 4.9 0.26 7434.3 
21.4 1744.2 1.2 0.08 1744.3 
94.1 843.9 0.8 0.09 844 
166 514.2 0.7 0.09 514.2 
NaI(Tl) based 
 
166.5 482.1 0.6 0.08 482.2 
838.4 6.4 0.1 0.03 6.4 
HPGe based 
 838.4 6.4 0.1 0.03 6.4 
 
Table no. 13 Total Body Activity Image based, NaI(Tl) and HPGe based respectively, at different time 
points for all contributing terms – Patient 5 
 
Furthermore, the activity distribution at different time points is shown in the plot below: 
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Fig.  25. Plot on results from TB activity and Kidneys in Patient 5 
Furthermore the determination of the absorbed dose was calculated by fitting the activity data 
to a function for each particular organ, using OLINDA software. The absorbed dose 
determination for each organ was made in the unit of Gy. Below is shown the %ID, which is the 
activity in and organ, divided by the injected amount, in percent. 
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Case 1: Planar and SPECT  
 
ABSORBED DOSE [Gy] 
Case1 
Time p.i. [h] REMAINDER KIDNEYS LIVER SPLEEN 
 
0.2 93.1 2 4.3 0.4 
21.4 16.9 1.5 4.6 0.5 
94.1 7.9 0.4 2.8 0.2 Kidneys Total Body 
166 4.9 0.1 1.9 0.1 2.8 0.3 
Case 2a: 177Lu1+177Lu2  
 
 
 
 
ABSORBED DOSE [Gy] 
Case 2a+2b 
Time p.i. [h] REMAINDER KIDNEYS LIVER SPLEEN 
 
 
 
 
 
0.2 93.1 2 4.3 0.4 
21.4 16.9 1.5 4.6 0.5 
94.1 7.9 0.4 2.8 0.2 
166 4.9 0.1 1.78 0.1 
838.4 0.06 0.00 0.02 0.00  Kidneys Total Body 
Case 2b: 177mLu 
3.0 0.3 
Time p.i. [h] REMAINDER KIDNEYS LIVER SPLEEN 
 
0.2 93.2 2 4.3 0.4 
21.4 18.4 1.6 5 0.6 
94.1 11.6 0.6 4.1 0.4 
166 9.6 0.3 3.5 0.2 
838.4 2 0.06 0.7 0.05  
Table no.14, ID% and Absorbed Dose for Kidneys and TB from: Case1: Planar and SPECT, 
Case2a: 177Lu1+177Lu2 and Case 2b: 177mLu for Patient 5 
 
Therefore, the absorbed dose based on the Planar and SPECT method, for the kidneys is 2.8 Gy 
and for the TB, 0. 3 Gy. The method based on the images and NaI(Tl) based measurements the 
absorbed dose results to be for the kidneys 3.0  Gy and for the total body 0.3 Gy. 
In addition, this particular patient was measured in a very close geometry at a very late time 
point. His 5th cycle of treatment with administered activity of 7395 MBq. The distance from 
HPGe detector system to an posterior view was 15 cm. The data in this particular case could not 
be analyzed because it was not possible to mark the ROI therefore, no activity determination 
was possible. Below an illustration is presented for the very late point time measurement, 
when data are not possible to be analyzed: 
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Fig. 26. Illustration from HPGe close geometry patient measurement at a late time point, upper panel 
from Maestro plot, lower panel the plot from the same measurement and decay of 177mLu 
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PATIENT 6 
The 1st measurement was performed 7 days after the 2nd cycle of radiotherapy administration 
with the activity of 7545 MBq. using both NaI(TI) and HPGe detector systems for anterior and 
posterior measurements at a distance 310 cm and 290 cm respectively. The data acquisition 
time for NaI(TI) detector was 294.9 s (anterior) and 294 s (posterior). For measurements 
performed with HPGe the data acquisition time was 290.9 s (anterior) and 289.6 s (posterior). 
The 2nd measurement was performed using only NaI(TI) detector system for anterior and 
posterior measurements at a distance 120 cm and 124 cm, respectively. The data acquisition 
time was 299.4 s (anterior) and 299.3 s (posterior).  
The 3rd measurement at a distance 133 cm for both measurement geometries was performed 
after 70 days from the date of administration. The data acquisition time was set to 599.2 s 
(anterior) and 599.1 s (posterior). 
The data analysis showed that the Activity in the TB after 7 days period, based on the image 
based method was 465.2 MBq (after 167 hours), while for a NaI(Tl) based method it showed to 
be 383.8 MBq, while for HPGe, 327.8 MBq.  
TOTAL BODY ACTIVITY [MBq] 
Image based Time p.i. [h] 177Lu1 177mLu 177Lu2 177Lu1 + 177Lu2 
 
0.5 7521.4 4.5 0.15 7521.6 
23.1 1759.5 1.1 0.06 1759.6 
94.6 852.3 0.7 0.07 852.3 
167.0 465.2 0.5 0.07 465.2 
NaI(Tl) based 
 166.8 383.8 0.4 0.05 383.9 
HPGe based 
 166.8 327.8 0.4 0.05 327.8 
 
Table no. 15 Total Body Activity Image based, NaI(Tl) and HPGe based respectively, at different time 
points for all contributing terms – Patient 6 
 
Furthermore, the activity distribution at different time points is shown in the plot below: 
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Fig.  27. Plot on results from TB activity and Kidneys in Patient 6 
Furthermore the determination of the absorbed dose was calculated by fitting the activity data 
to a function for each particular organ, using OLINDA software. The absorbed dose 
determination for each organ was made in the unit of Gy. Below is shown the %ID, which is the 
activity in and organ, divided by the injected amount, in percent. 
0.001 
0.010 
0.100 
1.000 
10.000 
100.000 
1000.000 
10000.000 
0 200 400 600 800 1000 1200 1400 
Ac
tiv
ity
 [M
Bq
] 
Time p.i [hours] 
Total Body Activity, Pat 6 
Image based, 
177Lu1 
NaI(Tl), 177Lu1 
HPGe, 177Lu1 
177mLu, Image and 
NaI(Tl) 
0.0001 
0.0010 
0.0100 
0.1000 
1.0000 
10.0000 
100.0000 
1000.0000 
0 200 400 600 800 1000 1200 1400 
Ac
tiv
ity
 [M
Bq
] 
Time P.I [hours] 
Kidneys, Pat 6 
177Lu1 
 177mLu 
177Lu2 
 77 | P a g e  
 
Case 1: Planar and SPECT  
 
ABSORBED DOSE [Gy] 
Case1 
Time p.i. [h] REMAINDER KIDNEYS LIVER SPLEEN 
 
0.5 94.5 2.1 2.6 0.7 
2317 18.4 1.2 2 1 
94.6 9.2 0.7 1 0.5 Kidneys Total Body 
167.0 5.1 0.3 0.5 0.3 4.8 0.4 
Case 2a: 177Lu1+177Lu2  
 
 
 
 
ABSORBED DOSE [Gy] 
Case 2a+2b 
Time p.i. [h] REMAINDER KIDNEYS LIVER SPLEEN 
 
 
 
 
 
0.5 94.5 2.1 2.6 0.7 
23.1 18.4 2 2 1 
94.6 9.2 0.7 1 0.5 
167.0 5.1 0.3 0.5 0.3 
      Kidneys Total Body 
Case 2b: 177mLu 
5.2 0.4 
Time p.i. [h] REMAINDER KIDNEYS LIVER SPLEEN 
 
0.5 94.8 2.1 2.7 0.7 
23.1 20.2 2.1 2.2 1.1 
94.6 13.5 1 1.4 0.8 
167.0 10 0.6 1 0.5 
Table no.16, ID% and Absorbed Dose for Kidneys and TB from: Case1: Planar and SPECT, 
Case2a: 177Lu1+177Lu2 and Case 2b: 177mLu for Patient 6 
 
Therefore, the absorbed dose based on the Planar and SPECT method, for the kidneys is 4.8 Gy 
and for the TB, 0. 4 Gy. The method based on the images and NaI(Tl) based measurements the 
absorbed dose results to be for the kidneys 5.2 Gy and for the total body 0.4 Gy. 
 
PATIENT 7 
The 1st measurement was performed 7 days after the 6th cycle of radiotherapy administration 
with the activity of 7435 MBq using both NaI(TI) and HPGe detector systems for anterior and 
posterior measurements at a distance 310 cm and 290 cm respectively. The data acquisition 
time for NaI(TI) detector was 288.3 s (anterior) and 287.4 s (posterior), while for measurements 
performed with HPGe the data acquisition time was 279.1 s (anterior) and 277.6 s (posterior). 
The 2nd measurement was performed using NaI(TI) detector system only, for both anterior and 
posterior measurements at a distance 125 cm and 120 cm, respectively. The data acquisition 
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time was 299.5 s (anterior) and 299.4 s (posterior). The data analysis showed that the Activity in 
the TB after 7 days period, based on the image based method was 1081.5 MBq (after 167 
hours), while for a NaI(Tl)  based method it shows to be 1002.7 MBq and for HPGe, it showed to 
be 840.5 MBq.. For a later time point (after 48 days) the Activity for NaI(Tl) based method  0.6 
MBq.  
TOTAL BODY ACTIVITY [MBq] 
Image based Time p.i. [h] 177Lu1 177mLu 177Lu2 177Lu1 + 177Lu2 
 
0.3 7411.8 4.4 0.15 7412 
20.8 4673 3 0.15 4673 
93.5 2201 1.9 0.18 2201.2 
167.7 1081.5 1.3 0.16 1081.7 
NaI(Tl) based 
 
167.2 1002.7 1.2 0.15 1002.8 
1164.0 0.6 0.04 0.01 0.6 
HPGe based 
 167.1 840.5 1 0.13 840.7 
 
Table no. 17 Total Body Activity Image based, NaI(Tl) and HPGe based, respectively, at different time 
points for all contributing terms – Patient 7 
 
Furthermore, the activity distribution at different time points is shown in the plot below:
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Fig.  28. Plot on results from TB activity and Kidneys in Patient 7  
Furthermore the determination of the absorbed dose was calculated by fitting the activity data 
to a function for each particular organ, using OLINDA software. The absorbed dose 
determination for each organ was made in the unit of Gy. Below is shown the %ID, which is the 
activity in and organ, divided by the injected amount, in percent. 
 Case 1: Planar and SPECT  
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Time p.i. [h] REMAINDER KIDNEYS LIVER SPLEEN 
 
0.3 85.6 1.2 13.2 0 
20.8 49.9 1 12.1 0 
93.5 23 0.4 6.3 0 Kidneys Total Body 
167.7 11.3 0.2 3.1 0 2.9 0.9 
Case 2a: 177Lu1+177Lu2  
 
 
 
 
ABSORBED DOSE [Gy] 
Case 2a+2b 
Time p.i. [h] REMAINDER KIDNEYS LIVER SPLEEN 
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20.8 54.4 1.1 13.2 0 
93.5 33.8 0.6 9.2 0 
167.7 22.4 0.5 6.2 0 
1164.0 0.8 0.01 0.2 0  
 
Table no.19, ID% and Absorbed Dose for Kidneys and TB from: Case1: Planar and SPECT, 
Case2a: 177Lu1+177Lu2 and Case 2b: 177mLu for Patient 7 
 
Therefore, the absorbed dose based on the Planar and SPECT method, for the kidneys is 2.9 Gy 
and for the TB, 0.9 Gy. The method based on the images and NaI(Tl) based measurements the 
absorbed dose results to be for the kidneys 3.7 Gy and for the total body 1.0 Gy. The absorbed 
doses for the TB activity and for Kidneys for six (6) patients, are shown in the plots below: 
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Fig.29, Plot on Absorbed doses from patients in TB and Kidneys 
 
Thus, as seen in the plot for the “Case1” the absorbed dose for the total body shows a higher 
activity for Patient 7 with 0.9 Gy, Patient 2 with 0.70 Gy, Patient 3 with 0.5 Gy  while comparing 
to the above mentioned Patient 6 and 4 the absorbed fraction ranges from 0.3-0.4 Gy. 
Meanwhile as regards to the kidney absorbed dose patient 2 with the highest absorbed dose of 
5.3 Gy and the lowest absorbed dose for patient 5. Similarly for “Case 2”. 
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XV. Discussion 
The Activity determination for the TB for specific geometry varies and depends on the detector 
systems used, time point and measurement time. As seen above (under Results Chapter) 
different Activity [MBq] have been administrated to the patients who were part of this research 
study, ranging from the lowest of 7145 MBq to the highest Activity of 7545 MBq. 
The data analysis shows that even after the 2nd  time point measurement, after 34 days still 
there is a measurable activity in the TB, more specifically as seen in Patient no.2. Furthermore, 
for the same case at 3rd time point of the measurement conducted after 61 days (from the 
radiotherapy administration date), there is still a measurable activity.  
The research addresses a question what is the impact of  177mLu fraction at this time point 
taking into account an approximate 2 month period from the administration?.  Moreover, when 
would be the time point that this high activity would not be present in the TB? For this purpose 
a better and reliable conclusion would be to perform images at a later time point, by estimating 
the activity concentration, its distribution and dose organs activity. 
However, taking into account that the existing activity of 177Lu and 177mLu at 208 keV peak by 
considering the contribution of both activities as sum between each of the radionuclides and 
based on the decay scheme of 177mLu, it shows that the activity of 177Lu is a basis generating 
from two sources: 
 The radionuclide production of 177Lu; and 
 The 177Lu  which is build-up as a product of the decay of the 177mLu  
Encountering the Activity of 177Lu at injected time in MBq assuming the 0.05% impurity (as a 
worse case “scenario”), the 177mLu activity from total activity of the 177Lu , one can estimated by 
the Radionuclide Purity (RNP): 
    𝑅𝑁𝑃 = 𝐴177𝐿𝑢
𝐴𝑇𝑜𝑡𝑎𝑙
 ∙ 100%           (28) 
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From the radionuclide administration for instance with 7400 MBq at day 30 the activity 
of 177Lu1 is 337.23 MBq, Activity of 177m Lu is 3.25 MBq, and total Activity including all the 
contributing terms is 341.18 MBq. Furthermore, the fraction of total Activity for  177mLu is 0.01 
at day 30 and increases over time, and at day 76 it “matches” the  177Lu, while being 0.43, at the 
time point when the activity of  177Lu is only 2.96 MBq and  177mLu activity is 2.66 MBq and  it 
starts to dominate at a later time point where the fraction of total activity will be 0.75, and the 
Activity of  177Lu is 0.28 MBq, while the Activity of  177mLu remains  2.41 MBq. Additionally, 
the  177Lu2 is 0 until day 40 and it increases in a small fraction over time, by “matching” 
the 177Lu at day 91 when the Activity of  177Lu is only 0.63 MBq and the Activity of  177mLu is 2.50 
MBq. It increases in a small fraction over time. 
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XVI. Conclusions 
Based on the key findings up to this stage of the research project, the Activity distribution at 
different time points and the prediction of renal retention toxicity is of complex issue. Within 
this context, further research is essential, by implying additional investigation methods, in order 
to bring the major conclusions and answer specific research questions within this frame.  
Performing the measurements with both NaI(TI) and HPGe detectors for all time points would 
provide a better estimation and a reliable results on the measurements performed until this 
stage of the project. Also, a specific time point for all measurements would better address the 
activity distribution of 177Lu. As already discussed in the chapter above (under Results) the 
administrated Activity with 177Lu of a slight difference from patient to patient, and the 2nd time 
point measurement was varying between all. Therefore, having a ‘fixed’ time point possibility 
for the measurements, for instance: one month after the treatment, would allow accurate 
conclusions driven by results. 
 By taking the long-term retention of 177Lu /177mLu into account, we have estimated that the  
absorbed dose values for patients should be increased by on average 8±2 % for the total-body 
and 10±8 % for the kidneys. It is acknowledged that these estimates are based on a worst case 
scenario, since we have assumed that the amount of 177mLu is 0.05% of the total activity at the 
time of radionuclide production. Also the assumption has been made that the activity 
distribution at the late time point measurement is the same in the patient body, as it was on 
the 7th day after activity administration. An interesting future improvement may be to make an 
image of the radionuclide distribution at a late time point. By any means, there is still activity in 
the patient body that can be measured at 30 days after administration, and the current work 
has made calculations based on these measurements, to estimate the absorbed dose including 
these new long-term retention measurements. 
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APPENDIX III      ENERGY RESOLUTION 
NaI(Tl) detector and HPGe detector 
-Manual Calculation 
NaI(Tl) 
Radioisotope Energy KeV Full Peak Scatter 
Background 
Peak height 
above bkg 
Counts at 
half max 
Energy @Ex1  
[keV] 
Energy @Ex2  
[keV] 
FWHM ΔE ΔE (%) 
57Co 122 3208 1626 1582 2417 114 126 12 0.098 9.84 
133Ba 208 3027 364.5 2662.5 1695.75 195 214 19 0.091 9.13 
137Cs 662 1328 168.0 1160.0 748 639 684 45 0.067 6.80 
HPGE 
Radioisotope Energy KeV Full Peak Scatter 
Background 
Peak height 
above bkg 
Counts at 
half max 
Energy @Ex1  
[keV] 
Energy @Ex2  
[keV] 
FWHM ΔE ΔE (%) 
57Co 122 294 37 257 165.5 120 123 3 0.0245 2.46 
133Ba 208 7028 36.5 6991.5 3532.25 207.17 208.61 1.44 0.0069 0.69 
137Cs 662 310 45 265 177.5 660 663 3 0.0045 0.45 
 
- Maestro Calculation 
NaI(Tl) 
Radioisotope Energy KeV FWHM ΔE ΔE (%) 
57Co 122 13.29 0.1089 10.89 
133Ba 208 4.11 0.0197 1.98 
137Cs 662 24.35 0.0367 3.68 
HPGe 
Radioisotope Energy KeV FWHM ΔE ΔE (%) 
57Co 121.94 1.28 0.0104 1.05 
133Ba 208.39 1.46 0.0070 0.70 
137Cs 661.65 1.65 0.0024 0.25 
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Model calculation from 137Cs 
NaI(Tl) l 
Radioisotope Energy KeV ΔE (%) - Manual ΔE (%) - Maestro 
57Co 122 15.83 8.57 
133Ba 208 12.13 6.56 
137Cs 662 6.80 3.68 
HPGe 
Radioisotope Energy KeV ΔE (%) - Manual ΔE (%) - Maestro 
57Co 122 1.06 0.58 
133Ba 208 0.81 0.44 
137Cs 662 0.45 0.25 
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APPENDIX IV    ACTIVITY OF REFERENCE SOURCES 
 
 
 
 
 
 
 
 
 
NaI(Tl) 
Radioactive 
source 
Original 
Activity 
Half life Original date Elapsed time  Formula           Λ Activity  
[MBq] 
Activity  
[Bq] 
57Co 22.2 MBq 272 days 01.02.2006 2296 days   
A=Ao*e^-λt 
 
0.0693 days^-1 
0.06 63871.29 
133Ba 4.31 MBq 3832.5 days 25.03.2002 3705 days  2.21 2205271.02 
133Ba 8.62  MBq 3832.5 days 25.03.2002 3705 days  4.41 4410542.05 
137Cs 346 kBq 30.7 years 8.2003 9.5 years  0.28 279205.19 
HPGe 
57Co 7.4 MBq 272 days 01.02.2006 2338 days   
 
A=Ao*e^-λt 
 
 
0.0693 days^-1 
0.02 19129.42 
57Co 14.8 MBq 272 days 01.02.2006 2338 days  0.04 38258.84 
57Co               * 22.2 MBq 272 days 01.02.2006 2338 days  0.06 57388.26 
133Ba 4.31 MBq 3832.5 days 25.03.2002 3737 days  2.19 2188582.95 
133Ba 8.62 MBq 3832.5 days 25.03.2002 3747 days  4.38 4377165.91 
137Cs 346 kBq 30.7 years 08.2003 9.5 years  0.28 279205.20 
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APPENDIX V THEORITICAL ASSUMTION OF 177Lu and 177mLu Activity determination 
177Lu  177mLu 
Ao 177Lu 
[MBq] 
Half-life 177Lu  
[h] 
       λ 
[1/h] 
Elapsed 
time[h] 
A (177Lu) 
[MBq] 
Ao 177mLu 
[MBq] 
Half-life 177mLu  
[hours] 
       λ 
[1/h] 
Elapsed 
time [h] 
A (177mLu) 
[MBq] 
 
 
 
7396.3 
 
 
 
161.52 
 
 
 
0.00429 
24 6672.44  
 
 
3.7 
 
 
 
3849.6 
 
 
 
0.00018 
24 3.68 
48 6019.43 48 3.67 
72 5430.32 72 3.65 
96 4898.87 96 3.64 
120 4419.43 120 3.62 
144 3986.92 144 3.61 
168 3596.73 168 3.59 
192 3244.73 192 3.57 
216 2927.17 216 3.56 
240 2640.70 240 3.54 
264 2382.26 264 3.53 
288 2149.12 288 3.51 
312 1938.79 312 3.50 
336 1749.04 336 3.48 
360 1577.87 360 3.47 
384 1423.45 384 3.45 
408 1284.14 408 3.44 
432 1158.46 432 3.42 
456 1045.09 456 3.41 
480 942.81 480 3.39 
504 850.54 504 3.39 
528 767.30 528 3.36 
552 692.20 552 3.35 
576 624.46 576 3.34 
600 563.35 600 3.32 
624 508.21 624 3.31 
648 458.48 648 3.29 
672 413.61 672 3.28 
696 373.13 696 3.26 
720 336.61 720 3.25 
744 303.67 744 3.24 
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APPENDIX VI 
Determination of the activity of different source activity components (177Lu and 177mLu) from gamma-spectroscopy data in the 208 keV photopeak 
window 
Both 177mLu and  177Lu emit 208 keV gamma photons. In addition, due to the isomeric transition in the decay of 177mLu, a secondary amount of 177Lu is 
being built up. 
The measured count ratein the 208 keV energy window is thus due to: 
a. 177Lu nuclei that are directly obtained from radionuclide production, whose activity at time t we denote 𝐴177𝐿𝑢1(𝑡). 
b. 177mLu nuclei that are directly obtained from radionuclide production. These nuclei may decay though either β- -decay or isomeric transition. 
We denote the activity by 𝐴177𝑚𝐿𝑢(𝑡). 
c. 177Lu being built up in the isomeric transition branching of 177mLu. This activity we denote 𝐴177𝐿𝑢2(𝑡). 
 
Directly after radionuclide production no 177Lu has yet been produced by 177mLu. Let tref be the reference time for the radionuclide production of the 
radionuclide. The activity 𝐴177𝐿𝑢2�𝑡𝑟𝑒𝑓� is thus zero.If we by RNP denote the fraction of the total activity that is 
177Lu at tref (which according to the 
producer is > 0.9995, i.e. the amount of 177mLu < 0.0005), then for each of a-c above we get: 
𝐴177𝐿𝑢1�𝑡𝑟𝑒𝑓� = 𝑅𝑁𝑃 ∙ �𝐴177𝐿𝑢1�𝑡𝑟𝑒𝑓� + 𝐴177𝑚𝐿𝑢�𝑡𝑟𝑒𝑓�� = 𝑅𝑁𝑃 ∙ 𝐴𝑇𝑜𝑡�𝑡𝑟𝑒𝑓� 
 
(1) 
 
𝐴177𝑚𝐿𝑢�𝑡𝑟𝑒𝑓� = (1 − 𝑅𝑁𝑃) ∙ �𝐴177𝐿𝑢1�𝑡𝑟𝑒𝑓� + 𝐴177𝑚𝐿𝑢�𝑡𝑟𝑒𝑓�� = (1 − 𝑅𝑁𝑃) ∙ 𝐴𝑇𝑜𝑡�𝑡𝑟𝑒𝑓� 
 
(2) 
𝐴177𝐿𝑢2�𝑡𝑟𝑒𝑓� = 0 
 
(3) 
 
At an arbitrary time, tm, after radionuclide production we get the following activities: 
𝐴177𝐿𝑢1(𝑡𝑚) = 𝑅𝑁𝑃 ∙ 𝐴𝑇𝑜𝑡�𝑡𝑟𝑒𝑓� ∙  𝑒𝑥𝑝(−𝜆177𝐿𝑢𝑡𝑚) 
 
(4) 
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𝐴177𝑚𝐿𝑢(𝑡𝑚) = (1 − 𝑅𝑁𝑃) ∙ 𝐴𝑇𝑜𝑡�𝑡𝑟𝑒𝑓� ∙ 𝑒𝑥𝑝(−𝜆177𝑚𝐿𝑢𝑡𝑚) 
 
(5) 
𝐴177𝐿𝑢2(𝑡𝑚) = 0.217 𝐴177𝑚𝐿𝑢�𝑡𝑟𝑒𝑓� 𝜆177𝐿𝑢𝜆177𝐿𝑢 − 𝜆177𝑚𝐿𝑢 ∙ {𝑒𝑥𝑝(−𝜆177𝑚𝐿𝑢𝑡𝑚) − 𝑒𝑥𝑝(−𝜆177𝐿𝑢𝑡𝑚)} 
 
(6) 
where the latter equation results since the rate of decay of 177Lu2 is governed by the rate of decay of 177mLu, as can be seen by solving the differential 
equations governing serial decay. The factor 0.217 is the probability that 177mLu decays by isometric transition.  
The measured count rate from a point source in air, at time 𝑡𝑚, in the 208 keV photopeak energy window is a sum of the count rates due to each 
component: 
𝑅208(𝑡𝑚) = 𝑅208,177𝑚𝐿𝑢(𝑡𝑚)+ 𝑅208,177𝐿𝑢1(𝑡𝑚) +  𝑅208,177𝐿𝑢2(𝑡𝑚) = 
  = �𝐴177𝑚𝐿𝑢(𝑡𝑚) ∙  𝑛𝛾,208,177𝑚𝐿𝑢 + 𝐴177𝐿𝑢1(𝑡𝑚) ∙  𝑛𝛾,208,177𝐿𝑢 + 𝐴177𝐿𝑢2(𝑡𝑚) ∙  𝑛𝛾,208,177𝐿𝑢� ∙ 𝜖208 ∙ 𝑆4𝜋𝐷2 
 
(7) 
 
We now describe the relative contribution to the count rate from the different sources of 208 keV photons. Since the energy is the same (208 keV), 
and since measurement of these 208 keV photons is made in one geometry, we will further on omit the factors 𝜖208 ∙
𝑆
4𝜋𝐷2
 and write the equations in 
terms of fractions of the total photon emission rate𝑁208,𝑇𝑜𝑡(𝑡𝑚) (number of emitted 208 keV photons per second), as given by: 
𝑁208,𝑇𝑜𝑡(𝑡𝑚) = 𝑁208,177𝑚𝐿𝑢(𝑡𝑚)+ 𝑁208,177𝐿𝑢1(𝑡𝑚) +  𝑁208,177𝐿𝑢2(𝑡𝑚) 
 =  𝐴177𝑚𝐿𝑢(𝑡𝑚)𝑛𝛾,208,177𝑚𝐿𝑢 + 𝐴177𝐿𝑢1(𝑡𝑚)𝑛𝛾,208,177𝐿𝑢 + 𝐴177𝐿𝑢2(𝑡𝑚)𝑛𝛾,208,177𝐿𝑢 
 
 = (1 − 𝑅𝑁𝑃) ∙ 𝐴𝑇𝑜𝑡�𝑡𝑟𝑒𝑓� ∙ 𝑒𝑥𝑝(−𝜆177𝑚𝐿𝑢 𝑡𝑚) ∙  𝑛𝛾,208,177𝑚𝐿𝑢 + 𝑅𝑁𝑃 ∙ 𝐴𝑇𝑜𝑡�𝑡𝑟𝑒𝑓� ∙ 𝑒𝑥𝑝(−𝜆177𝐿𝑢𝑡𝑚)  ∙ 𝑛𝛾,208,177𝐿𝑢+ 0.217 ∙  (1 − 𝑅𝑁𝑃) ∙ 𝐴𝑇𝑜𝑡�𝑡𝑟𝑒𝑓�  ∙  𝜆177𝐿𝑢  ∙ 𝑛𝛾,208,177𝐿𝑢
𝜆177𝐿𝑢 − 𝜆177𝑚𝐿𝑢
{𝑒𝑥𝑝(−𝜆177𝑚𝐿𝑢𝑡𝑚) − 𝑒𝑥𝑝(−𝜆177𝐿𝑢𝑡𝑚)} 
 
(8) 
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We form the ratios, F, of the rates of photon emission of each of the components a-cto the total photon emission rate: 
𝑁177𝐿𝑢1(𝑡𝑚) = 𝑁208,𝑇𝑜𝑡(𝑡𝑚) ∙ �𝑁177𝐿𝑢1(𝑡𝑚)𝑁208,𝑇𝑜𝑡(𝑡𝑚)� = 𝑁208,𝑇𝑜𝑡(𝑡𝑚) ∙ 𝐹177𝐿𝑢1(𝑡𝑚) 
 
(9) 
𝑁177𝑚𝐿𝑢(𝑡𝑚) = 𝑁208,𝑇𝑜𝑡(𝑡𝑚) ∙ �𝑁177𝑚𝐿𝑢(𝑡𝑚)𝑁208,𝑇𝑜𝑡(𝑡𝑚)� = 𝑁208,𝑇𝑜𝑡(𝑡𝑚) ∙ 𝐹177𝑚𝐿𝑢(𝑡𝑚) 
 
(10) 
𝑁177𝐿𝑢2(𝑡𝑚) = 𝑁208,𝑇𝑜𝑡(𝑡𝑚) ∙ �𝑁177𝐿𝑢2(𝑡𝑚)𝑁208,𝑇𝑜𝑡(𝑡𝑚)� = 𝑁208,𝑇𝑜𝑡(𝑡𝑚) ∙ 𝐹177𝐿𝑢2(𝑡𝑚) 
 
(11) 
 
For source component a: 
𝐹177𝐿𝑢1(𝑡𝑚) = 𝑁177𝐿𝑢1(𝑡𝑚)𝑁208,𝑇𝑜𝑡(𝑡𝑚) = �𝑁208,𝑇𝑜𝑡(𝑡𝑚)𝑁177𝐿𝑢1(𝑡𝑚)�−1 
 
with 
 
𝑁208,𝑇𝑜𝑡(𝑡𝑚)
𝑁177𝐿𝑢1(𝑡𝑚) = �(1 − 𝑅𝑁𝑃) ∙ 𝐴𝑇𝑜𝑡�𝑡𝑟𝑒𝑓� ∙ 𝑒𝑥𝑝(−𝜆177𝑚𝐿𝑢 𝑡𝑚) ∙  𝑛𝛾,208,177𝑚𝐿𝑢 + 𝑅𝑁𝑃 ∙ 𝐴𝑇𝑜𝑡�𝑡𝑟𝑒𝑓� ∙ 𝑒𝑥𝑝(−𝜆177𝐿𝑢𝑡𝑚) ∙  𝑛𝛾,208,177𝐿𝑢+ 0.217 (1 − 𝑅𝑁𝑃) ∗ 𝐴𝑇𝑜𝑡�𝑡𝑟𝑒𝑓�𝜆177𝐿𝑢𝑛𝛾,208,177𝐿𝑢
𝜆177𝐿𝑢 − 𝜆177𝑚𝐿𝑢
{𝑒𝑥𝑝(−𝜆177𝑚𝐿𝑢𝑡𝑚) − 𝑒𝑥𝑝(−𝜆177𝐿𝑢𝑡𝑚)}�  / 
�𝑅𝑁𝑃 ∗ 𝐴𝑇𝑜𝑡�𝑡𝑟𝑒𝑓�� ∙ 𝑒𝑥𝑝(−𝜆177𝐿𝑢𝑡𝑚) ∙  𝑛𝛾,208,177𝐿𝑢 
 
 
=1 + �𝑛𝛾,208,177𝑚𝐿𝑢
𝑛𝛾,208,177𝐿𝑢 � �1−𝑅𝑁𝑃𝑅𝑁𝑃 � ∙ �𝑒𝑥𝑝�(𝜆177𝐿𝑢 − 𝜆177𝑚𝐿𝑢 )𝑡𝑚�  + � 𝜆177𝐿𝑢  0.217  𝜆177𝐿𝑢−𝜆177𝑚𝐿𝑢�  ∙ �𝑒𝑥𝑝�(𝜆177𝐿𝑢 − 𝜆177𝑚𝐿𝑢)𝑡𝑚� − 1�� 
 
(12) 
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For source component b: 
𝐹177𝑚𝐿𝑢(𝑡𝑚)  = 𝑁177𝑚𝐿𝑢(𝑡𝑚)𝑁208,𝑇𝑜𝑡(𝑡𝑚) = �𝑁208,𝑇𝑜𝑡(𝑡𝑚)𝑁177𝑚𝐿𝑢(𝑡𝑚)�−1 
 
with 
 
𝑁208,𝑇𝑜𝑡(𝑡𝑚)
𝑁177𝑚𝐿𝑢(𝑡𝑚) = 1 + � 𝑛𝛾,208,177𝐿𝑢
𝑛𝛾,208,177𝑚𝐿𝑢� �� 𝑅𝑁𝑃1 − 𝑅𝑁𝑃� ∙ 𝑒𝑥𝑝�(𝜆177𝑚𝐿𝑢 − 𝜆177𝐿𝑢)𝑡𝑚�  + 𝜆177𝐿𝑢0.217  𝜆177𝐿𝑢 − 𝜆177𝑚𝐿𝑢 ∙ �1 − 𝑒𝑥𝑝�(𝜆177𝑚𝐿𝑢 − 𝜆177𝐿𝑢)𝑡𝑚��� 
 
(13) 
 
For source component c: 
𝐹177𝐿𝑢2(𝑡𝑚)  = 𝑁177𝐿𝑢2(𝑡𝑚)𝑁208,𝑇𝑜𝑡(𝑡𝑚) = �𝑁208,𝑇𝑜𝑡(𝑡𝑚)𝑁177𝐿𝑢2(𝑡𝑚)�−1 
 
with 
 
𝑁208,𝑇𝑜𝑡(𝑡𝑚)
𝑁177𝐿𝑢2(𝑡𝑚) = 
 
=
(𝜆177𝐿𝑢−𝜆177𝑚𝐿𝑢) 𝑒𝑥𝑝(−𝜆177𝑚𝐿𝑢 𝑡𝑚)𝑛𝛾,208,177𝑚𝐿𝑢
𝜆177𝐿𝑢0.217 𝑛𝛾,208,177𝐿𝑢�𝑒𝑥𝑝(−𝜆177𝑚𝐿𝑢𝑡𝑚)−𝑒𝑥𝑝(−𝜆177𝐿𝑢𝑡𝑚)� + � 𝑅𝑁𝑃1−𝑅𝑁𝑃� (𝜆177𝐿𝑢−𝜆177𝑚𝐿𝑢) 𝑒𝑥𝑝(−𝜆177𝐿𝑢𝑡𝑚)𝜆177𝐿𝑢0.217 �𝑒𝑥𝑝(−𝜆177𝑚𝐿𝑢𝑡𝑚)−𝑒𝑥𝑝(−𝜆177𝐿𝑢𝑡𝑚)� + 1 
 = 1 + (𝜆177𝐿𝑢 − 𝜆177𝑚𝐿𝑢)
𝜆177𝐿𝑢0.217 ��𝑛𝛾,208,177𝑚𝐿𝑢𝑛𝛾,208,177𝐿𝑢 �  1 �1 − 𝑒𝑥𝑝�(𝜆177𝑚𝐿𝑢 − 𝜆177𝐿𝑢)𝑡𝑚�� + � 𝑅𝑁𝑃1 − 𝑅𝑁𝑃� 1�𝑒𝑥𝑝�(𝜆177𝐿𝑢 − 𝜆177𝑚𝐿𝑢)𝑡𝑚� − 1�� 
 
(14) 
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The activity of each source component is then given by: 
𝐴177𝐿𝑢1(𝑡𝑚) = 𝑁177𝐿𝑢1(𝑡𝑚)𝑛𝛾,208,177𝐿𝑢 = 𝑁208,𝑇𝑜𝑡(𝑡𝑚)𝑛𝛾,208,177𝐿𝑢 ∙ �𝑁177𝐿𝑢1(𝑡𝑚)𝑁208,𝑇𝑜𝑡(𝑡𝑚)� =   𝑅208(𝑡𝑚)𝜖208 ∙ 𝑆4𝜋𝐷2 ∙ 𝐹177𝐿𝑢1(𝑡𝑚)𝑛𝛾,208,177𝐿𝑢  
 
 
(15) 
𝐴177𝑚𝐿𝑢(𝑡𝑚) = 𝑁177𝑚𝐿𝑢(𝑡𝑚)𝑛𝛾,208,177𝑚𝐿𝑢 = 𝑁208,𝑇𝑜𝑡(𝑡𝑚)𝑛𝛾,208,177𝑚𝐿𝑢 ∙ �𝑁177𝑚𝐿𝑢(𝑡𝑚)𝑁208,𝑇𝑜𝑡(𝑡𝑚)� =   𝑅208(𝑡𝑚)𝜖208 ∙ 𝑆4𝜋𝐷2 ∙ 𝐹177𝑚𝐿𝑢(𝑡𝑚)𝑛𝛾,208,177𝑚𝐿𝑢  
 
(16) 
𝐴177𝐿𝑢2(𝑡𝑚) = 𝑁177𝐿𝑢2(𝑡𝑚)𝑛𝛾,208,177𝐿𝑢 = 𝑁208,𝑇𝑜𝑡(𝑡𝑚)𝑛𝛾,208,177𝐿𝑢 ∙ �𝑁177𝐿𝑢2(𝑡𝑚)𝑁208,𝑇𝑜𝑡(𝑡𝑚)� =   𝑅208(𝑡𝑚)𝜖208 ∙ 𝑆4𝜋𝐷2 ∙ 𝐹177𝐿𝑢2(𝑡𝑚)𝑛𝛾,208,177𝐿𝑢  
 
(17) 
 
 
 
 
 
 
 
 
 
 
 
 100 | P a g e  
 
APPENDIX VII     PHOTOPEAK EFFICIENCY 
NaI(Tl) detector 
 
Reference 
source 
 
R 
Detector 
diameter  
[cm] 
Source-
detector 
distance 
[cm] 
Photon 
energy  
[keV] 
 
n-gamma 
 
    A [Bq] 
 
      ϵ 
 
Radioisotope 
 
Energy  
[keV] 
Approx. 
 
       ϵ 
57Co 26.03  
        7.62 
 
               74 
122 0.856 63871.29 0.718 177Lu 208 0.61 
133Ba(1)  387.47 356 0.621 2205271.02 0.427 177Lu 378 0.419 
133Ba(2)  784.75 356 0.621 4410542.05 0.433 177Lu 418 0.41 
137Ba 60.40 662 0.851 279205.19 0.384 New 
calibrated 177Lu 
208 0.649 
HPGe detctor 
57Co (1) 1.916  
 
 
 
 
         5 
 
 
 
 
 
            74 
122 0.856 19129.42 0.410 177Lu 208 0.293 
57Co (2) 3.390 122 0.856 38258.84 0.363 177Lu 378 0.121 
57Co (3) 5.655 122 0.856 57388.26 0.403 177Lu 418 0.11 
133Ba(1) 40.712 81 0.3406 2188582.95 0.191 New 
calibrated 177Lu 
208 0.412 
 7.498 276 0.07164 2188582.95 0.168 
 18.035 302 0.1833 2188582.95 0.158 
 48.396 356 0.6205 2188582.95 0.125 
 6.283 384 0.0894 2188582.95 0.113 
133Ba(2) 85.950 81 0.3406 4377165.91 0.202 
 16.624 276 0.07164 4377165.91 0.186 
 38.703 302 0.1833 4377165.91 0.169 
 106.108 356 0.6205 4377165.91 0.137 
 14.176 384 0.0894 4377165.91 0.127 
137Cs 4.985 662 0.851 279205.19 0.074 
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APPENDIX VIII  STANDARD DEVIATION - EFFICIENCY 
Determination of Standard Deviation - The standard deviation 𝜎𝜖 shows the variation of the 
obtained results from measurements as an average mean. The calculation of standard deviation 
for performed measurements has been evaluated using the equation for the detected count 
rate [45]:  
𝑅 = 𝐴𝑈𝐶𝑛𝑒𝑡
𝑡
 =   𝐴 ∙  𝑛𝛾 ∙ 𝑆 𝐷2 ∙ 4𝜋 ∙∈     ⟺     ∈= 𝐷2 ∙ 4𝜋 ∙   𝐴𝑈𝐶𝑛𝑒𝑡 𝐴 ∙  𝑛𝛾 ∙ 𝑆 ∙ 𝑡  
where 𝐴𝑈𝐶𝑛𝑒𝑡 is the net area under the peak, and t is the measurement time. The other 
symbols are as before: A=activity in sample, 𝑛𝛾= the emitted number of photons per decay S 
=surface area of detector, D=source-detector distance, and 𝐷2 ∙ 4𝜋= the solid angle covered by 
detector. 
Derivation:      𝜎𝜖2 = � 𝜕∈𝜕 𝐴𝑈𝐶𝑛𝑒𝑡�2 ∙   𝜎  𝐴𝑈𝐶𝑛𝑒𝑡2 + �𝜕∈𝜕𝑡�2 ∙   𝜎𝑡2 + �𝜕∈𝜕𝐴�2 ∙   𝜎𝐴2 + � 𝜕∈𝜕𝑛𝛾�2 ∙   𝜎𝑛𝛾2  
+ �𝜕 ∈
𝜕𝑆
�
2
∙   𝜎𝑆2 + �𝜕 ∈𝜕𝐷�2 ∙   𝜎𝐷2 
Assuming that:  
𝜕 ∈
𝜕 𝐴𝑈𝐶𝑛𝑒𝑡 = 𝐷2 ∙ 4𝜋𝐴 ∙  𝑛𝛾 ∙ 𝑆 ∙ 𝑡 = ∈ 𝐴𝑈𝐶𝑛𝑒𝑡 
𝜕 ∈
𝜕𝐷
= 2𝐷 ∙ 4𝜋 ∙   𝐴𝑈𝐶𝑛𝑒𝑡
𝐴 ∙  𝑛𝛾 ∙ 𝑆 ∙ 𝑡 = 2𝐷  ∙ 𝜖 
𝜕 ∈
𝜕𝐴
= 𝐷2  ∙ 4𝜋 ∙   𝐴𝑈𝐶𝑛𝑒𝑡 𝑛𝛾 ∙ 𝑆 ∙ 𝑡 ∙ �− 1𝐴2� = − 1𝐴  ∙ 𝜖 
𝜎𝑡
2 = 0 
𝜎𝑛𝛾
2 = 0 
𝜎𝑆
2 = 0 
𝜎𝜖
2 = � ∈ 𝐴𝑈𝐶𝑛𝑒𝑡�2 ∙  𝜎  𝐴𝑈𝐶𝑛𝑒𝑡2 + �2𝐷  ∙∈�2 ∙  𝜎𝐷2+ �∈𝐴�2 ∙   𝜎𝐴2 = ∈2 ��𝜎  𝐴𝑈𝐶𝑛𝑒𝑡 𝐴𝑈𝐶𝑛𝑒𝑡�2 + �2𝜎𝐷𝐷 �2 + �𝜎𝐴𝐴 �2� 
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The uncertainty in the measured distance was assumed 2 cm. The uncertainty in the net area 
under the peak was determined from Maestro. In the following table the details of used 
reference sources are shown, including the reference date and uncertainty, giving  𝜎𝐴/A 
Nuclide Source no Activity (kBq) 𝝈𝑨/𝑨 (%) 
133Ba LW362 368 3 
137Cs LW363 346 3 
57Co LW364 406 3 
60Co LW365 392 3 
REFERENCE DATE: 1 AUGUST 2003 
Standard Deviation (for used reference sources) – NaI(Tl) 
Radionuclide Sigma 
AUCnet AUCnet 
SigmaAUCnet/ 
AUCnet 2*sigmaD/D SigmaA/A Efficiency 
Sigma 
Efficiency 
57Co 114 10392 0.01097 0.0541 0.03 0.72 0.045 
133Ba (1) 707 152850 0.00463 0.0541 0.03 0.43 0.026 
133Ba 1011 312614 0.00323 0.0541 0.03 0.43 0.027 
137Cs 271 24097 0.01125 0.0541 0.03 0.38 0.024 
 
Standard Deviation (for used reference sources) – HPGe 
Radionuclide Sigma 
AUCnet AUCnet 
SigmaAUCnet/ 
AUCnet 2*sigmaD/D SigmaA/A Efficiency 
Sigma 
Efficiency 
57Co (1) 19 573 0.0332 0.0541 0.03 0.410 0.029 
57Co (2) 33 1014 0.0326 0.0541 0.03 0.363 0.025 
57Co (3) 40 1691 0.0237 0.0541 0.03 0.403 0.027 
133Ba (1) 118 11969 0.0099 0.0541 0.03 0.191 0.012 
 43 2204 0.0195 0.0541 0.03 0.168 0.011 
 70 5302 0.0132 0.0541 0.03 0.158 0.010 
 123 14228 0.0086 0.0541 0.03 0.125 0.0078 
 41 1847 0.0222 0.0541 0.03 0.113 0.0074 
133Ba (2) 186 24839 0.0075 0.0541 0.03 0.202 0.013 
 70 4804 0.0146 0.0541 0.03 0.186 0.012 
 106 11185 0.0095 0.0541 0.03 0.169 0.011 
 173 30665 0.0056 0.0541 0.03 0.137 0.0085 
 63 4097 0.0154 0.0541 0.03 0.127 0.0081 
137Cs 40 1490 0.0268 0.0541 0.03 0.074 0.0050 
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APPENDIX IX   DISTANCE ESTIMATION for measurements with NaI(Tl)  
Efficiency for 177Lu and 177mLu (distance estimation)  Efficiency for 177Lu and 177mLu (distance estimation) 
Photon 
energy [keV] 
ϵ (CPS/Bq) n-gamma S (cm2) Photon 
energy [keV] 
ϵ (CPS/Bq) n-gamma S (cm2) 
208 0.61 0.11 14.52 208 0.650 0.11 14.52 
378 0.419 0.297 378 N/A 0.297 
418 0.41 0.213 418 N/A 0.213 
R/A (CPS/Bq) 
Distance 208 378 418  Distance 208 378 418 
100 7.76E-06,  1.44E-05 1.01E-05 100 8.26E-06 n/a n/a 
125 4.96E-96 9.20E-06 6.46E-06 125 5.29E-06 n/a n/a 
150 3.45E-06 6.39E-06 4.49E-06 150 3.67E-06 n/a n/a 
200 1.94E-06 3.60E-06 2.52E-06 200 2.07E-06 n/a n/a 
250 1.24E-06 2.30E-06 1.61E-06 250 1.32E-06 n/a n/a 
300 8.62E-07 1.60E-06 1.12E-06 300 9.18E-07 n/a n/a 
350 6.33E-07 1.17E-06 8.24E-07 350 6.74E-07 n/a n/a 
400 4.85E-07 8.99E-07 6.31E-07 400 5.16E-07 n/a n/a 
Note: Based on the efficiency determination for reference sources      Note: Based on the efficiency from the new 177Lu sample 
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APPENDIX X   Summary from previous measurements using HPGe detector (close geometry) 
Sample Identification: 177Lu no1 177Lu Serie 1 B1 177Lu Serie 1B2 177Lu det 3 no.3 177Lu det 2 no.3 177Lu det 3 no.2 177Lu det 3 no.2 177Lu det 2 no.2 177Lu det 2 no.1 177Lu Serie 1 B3 
Sample 
Description:   Burk 1/3 det 3 Serie 1 det 3             Serie 1 det 3 
Sample Type: 60ml-can 60ml-can 60ml-can 
1300ml-can-
vatska 
1300ml-can-
vatska 60ml-can 60ml-can 
1300ml-can-
vatska 60ml-can 60ml-can 
Sample size 5,700 E-02 kg 6,419 E-02 kg 6,955 E-02 kg 5,100 E-02 kg 5,100 E-02 kg 5,800 E-02 kg 5,800 E-02 kg 5,800 E-02 kg 5,800 E-02 kg 6,726E-02 kg 
Sample Taken 
On: 
2011-09-14 
11:01:45 
2011-09-14 
12:00:48 
2011-09-14 
12:00:51 
2011-09-14 
12:54:06 
2011-09-14 
13:11:42 
2011-09-14 
12:37:46 
2011-09-14 
12:12:16 
2011-09-14 
12:53:21 
2011-09-14 
12:11:37 
2011-09-14 
12:00:51 
Acquisition 
Started: 
2011-09-08 
12:04:26 
2012-01-26 
09:11:47 
2012-01-28 
09:43:29 
2011-11-08 
12:53:46 
2011-11-08 
13:11:23 
2011-11-08 
12:37:26 
2011-11-08 
12:12:58 
2011-11-08 
12:52:53 
2011-11-08 
12:12:52 
2012-01-26 
09:54:48 
Procedure: 
DET3_60ml-
can 1.0 g/cm3 
DET3_60ml-can 
1.0 g/cm3 
DET3_60ml-
can 1.0 g/cm3 
DET3_60ml-
can 1.0 g/cm3 
DET2_60ml-
can 1.0 
g/cm3 
DET2_60ml-
can 1.0 g/cm3 
DET2_60ml-
can 1.0 g/cm3 
DET2_60ml-
can 1.0 g/cm3 
DET2_60ml-
can 1.0 g/cm3 
DET3_60ml-
can 1.0 g/cm3 
Detector Name: ADC3 ADC3 ADC3 ADC3 ADC2 ADC3 ADC3 ADC2 ADC2 ADC3 
Geometry: 
60ml - can 1.0 
g/cm3 
60ml - can 1.0 
g/cm3 
60ml - can 1.0 
g/cm3 
60ml - can 1.0 
g/cm3 
60ml - can 
1.0 g/cm3 
60ml - can 1.0 
g/cm3 
60ml - can 1.0 
g/cm3 
60ml - can 1.0 
g/cm3 
60ml - can 1.0 
g/cm3 
60ml - can 1.0 
g/cm3 
Live Time: 87.1 s 825,2 s 584,3 s 543,7 s 344,1 s 261,8 s 129,1 s 143,5 s 127,6s 821,3 s 
Real Time: 91.0 s 841,2 s 596,3 s 568,0 s 360,4 s 273,7 s 135,0 s 150,5 s 133,7 s 837,1 s 
Dead Time 4.29% 1,89% 2.02% 4,28% 4,54% 4,34% 4,33% 4,64% 4,58% 1,89% 
Peak Locate 
Threshold 2.7 2.7 2.7 2.7 2.7 2.7 2.7 2.7 2.7 2.7 
Peak Locate 
Range (in 
channels): 1-4096 1-4096 1-4096 1-4096 1-4096 1-4096 1-4096 1-4096 1-4096 1-4096 
Peak Area 
Range (in 
channels): 1-4096 1-4096 1-4096 1-4096 1-4096 1-4096 1-4096 1-4096 1-4096 1-4096 
Identification 
Energy 
Tolerance: 1000 keV 1000 keV 1000 keV 1000 keV 1000 keV 1000 keV 1000 keV 1000 keV 1000 keV 1000 keV 
Energy 
Calibration Used 
Done on: 2011-07-04 2011-07-04 2011-07-04 2011-07-04 2011-06-10 2011-07-04 2011-07-04 2011-06-10 2011-06-10 2011-07-04 
Efficiency 
Calibration Used 
Done on: 2010-02-23 2010-02-23 2010-02-23 2010-02-23 2011-11-08 2010-02-23 2010-02-23 2011-11-08 2011-11-08 2010-02-23 
Sample 
Number: 6410 6398 6405 6418 6417 6413 6412 6414 6411 6409 
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Sample Identification: Lu-177 Serie 2 B1 Lu-177 Serie 2 B2 Lu-177 Serie 2B3 
Sample Description: Burk 1/3 det 2 Serie 2 det 2 Serie 2 det 2 
Sample Type: 60ml-can 60ml-can 60ml-can 
Sample size 6,845 E-02 kg 6,872 E-02 kg 6,816 E-02 kg 
Sample Taken On: 2011-09-28 12:00:48 2011-09-28 12:00:51 2011-09-28 12:00:51 
Acquisition Started: 2012-01-26 09:11:54 2012-01-26 09:43:35 2012-01-26 09:54:49 
Procedure: 
DET3_60ml-can 1.0 
g/cm3 
DET3_60ml-can 1.0 
g/cm3 
DET3_60ml-can 1.0 
g/cm3 
Detector Name: ADC2 ADC2 ADC2 
Geometry: 60ml - can 1.0 g/cm3 60ml - can 1.0 g/cm3 60ml - can 1.0 g/cm3 
Live Time: 923, 9 s 573,0 s 398,1 s 
Real Time: 940,9 s 584,3 s 406,4 s 
Dead Time: 1,81 % 1,93% 2.03% 
Peak Locate Threshold 2.7 2.7 2.7 
Peak Locate Range (in 
channels): 1-4096 1-4096 1-4096 
Peak Area Range (in 
channels): 1-4096 1-4096 1-4096 
Identification Energy 
Tolerance: 1000 keV 1000 keV 1000 keV 
Energy Calibration Used 
Done on: 2011-06-10 2011-07-04 2011-06-10 
Efficiency Calibration 
Used Done on: 2011-11-08 2010-02-23 2011-11-08 
Sample Number: 6402 6406 6407 
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Summary on Gamma Spectrum – Measurements of 177 Lu using HPGe detector (*Reports from APEX Programme) 
Sample Date Time Sample taken on: 
Acquisition 
started: 
Detector 
Name Live time Real time: Dead time 
Lu-177 no1 1/26/2012 10:17:58 9/14/2011 11:01 8-Nov-11 ADC3 87.1 s 91,0 s 4,29% 
Lu-177 Serie 1 B1 1/26/2012 9:33:36 9/14/2011 12:00 26-Jan-12 ADC3 825,2 s 841,2 s 1,89% 
Lu-177 Serie 1B2 1/26/2012 9:55:16 9/14/2011 12:00 28-Jan-12 ADC3 584,3 s 596,3 s 2.02% 
Lu det 3 no.3 1/26/2012 10:36:35 9/14/2011 12:54 8-Nov-11 ADC3 543,7 s 568,0 s 4,28% 
Lu 177 det 2 no.3 1/26/2012 10:34:20 9/14/2011 13:11 8-Nov-11 ADC2 344,1 s 360,4 s 4,54% 
Lu 177 det 3 no.2 1/26/2012 10:24:36 9/14/2011 12:37 8-Nov-11 ADC3 261,8 s 273,7 s 4,34% 
Lu 177 det 3 no.2 1/26/2012 10:20:20 9/14/2011 12:12 8-Nov-11 ADC3 129,1 s 135,0 s 4,33% 
Lu 177 det 2 no.2 1/26/2012 10:26:32 9/14/2011 12:53 8-Nov-11 ADC2 143,5 s 150,5 s 4,64% 
Lu-177 det 2 no1 1/26/2012 10:20:20 9/14/2011 12:11 9-Nov-11 ADC2 127,6 s 133,7 s 5,48% 
Lu-177 Serie 1 B3 1/26/2012 10:14:00 9/14/2011 12:00 10-Nov-11 ADC3 821,3 s 837,1 s 1,89% 
                  
Lu-177 Serie 2 B1 1/26/2012 9:44:21 9/28/2011 12:00 26-Jan-12 ADC2 923,9 s 940,9 s 1,81% 
Lu-177 Serie 2 B2 1/26/2012 9:58:21 9/28/2011 12:00 26-Jan-12 ADC2 573,0 s 584,3 s 1,93% 
Lu-177 Serie 2 B3 1/26/2012 10:09:19 9/28/2011 12:00 26-Jan-12 ADC2 398,1 s 406,4 s 2,03 % 
 
Measurements with HPGe detector system – Instructions from Supervisors* 
The spectra from the HPGe detector system were analyzed in APEX using a radionuclide library for 177mLu. A radionuclide library is a list of gamma-
peaks, their abundances, and the half-life of the radionuclide, in this case 177mLu.  At measurement the detector system was energy-calibrated. Also, 
the detector efficiency had been previously determined for different measurement geometries. This means that the efficiency given below also 
encompasses the effects of the measurement geometry, so that the geometry factor that we usually put in (S/4πD2) is a now part of the efficiency 
value ∈. This thus means that we do not need this geometry factor in the equations. 
Determination of activity of 177Lu 
If x is a gamma-energy that is: 
a) present in the decay scheme for 177mLu,  
b) is not present in the decay scheme for 177Lu,  
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c) is well detectable and separable in the measured spectrum. 
Its AUC is 𝐴𝑈𝐶𝑥,177𝑚𝐿𝑢 (unit cps) and the detector efficiency for that energy is 𝜖𝑥, then: 
𝐴𝑈𝐶𝑥,177𝑚𝐿𝑢 = 𝐴177𝑚𝐿𝑢(𝑀𝑒𝑎𝑠𝐷𝑎𝑡𝑒) ∗ 𝑛𝛾,𝑥,177𝑚𝐿𝑢 ∗ 𝜖𝑥 =>        (1) 
𝐴177𝑚𝐿𝑢(𝑀𝑒𝑎𝑠𝐷𝑎𝑡𝑒) = 𝐴𝑈𝐶𝑥,177𝑚𝐿𝑢𝑛𝛾,𝑥,177𝑚𝐿𝑢∗𝜖𝑥  
This activity value is then valid for the date of measurement (MeasDate). Since APEX gives the activity for a reference date (RefDate), the value given 
in the “nuclide MDA report” is therefore 
𝐴177𝑚𝐿𝑢(𝑅𝑒𝑓𝐷𝑎𝑡𝑒) = 𝐴𝑈𝐶𝑥,177𝑚𝐿𝑢𝑛𝛾,𝑥,177𝑚𝐿𝑢∗𝜖𝑥 𝑒𝑥𝑝(𝜆177𝑚𝐿𝑢 ∗ 𝑃𝑎𝑠𝑠𝑒𝑑𝑇𝑖𝑚𝑒)       (2) 
Where “PassedTime” is the time between the measurement and the reference date, and   
𝜆177𝑚𝐿𝑢 = ln (2)/𝑇1/2_177𝑚𝐿𝑢             (3) 
So, since there are several peaks, x, in the spectra that fulfill the criteria (a)-(c) above, we get several estimates of the activity 𝐴177𝑚𝐿𝑢(𝑅𝑒𝑓𝐷𝑎𝑡𝑒) 
from which we calculate an average to get the final value:  
𝐴177𝑚𝐿𝑢(𝑅𝑒𝑓𝐷𝑎𝑡𝑒)𝑓𝑖𝑛𝑎𝑙 = ∑   𝐴177𝑚𝐿𝑢(𝑅𝑒𝑓𝐷𝑎𝑡𝑒)𝑥𝑥          (4) 
For the 113 keV and the 208 keV peaks the measured AUC are really sums of the contributions from 177Lu and 177mLu activities. For instance for the 
208 keV peak: 
𝐴𝑈𝐶208 = 𝐴𝑈𝐶208,177𝑚𝐿𝑢+ 𝐴𝑈𝐶208,177𝐿𝑢 =          (5) = 𝐴177𝑚𝐿𝑢(𝑀𝑒𝑎𝑠𝐷𝑎𝑡𝑒) ∗ 𝑛𝛾,208,177𝑚𝐿𝑢 ∗ 𝜖208 + 𝐴177𝐿𝑢(𝑀𝑒𝑎𝑠𝐷𝑎𝑡𝑒) ∗ 𝑛𝛾,208,177𝐿𝑢 ∗ 𝜖208 = �𝐴177𝑚𝐿𝑢(𝑀𝑒𝑎𝑠𝐷𝑎𝑡𝑒) ∗ 𝑛𝛾,208,177𝑚𝐿𝑢 + 𝐴177𝐿𝑢 ∗ 𝑛𝛾,208,177𝐿𝑢(𝑀𝑒𝑎𝑠𝐷𝑎𝑡𝑒)� ∗ 𝜖208 
The activity values given in the Report-list are then not correct since they are calculated by the assumption that it is only 177mLu that is present. If we 
call the activity value given in the Report-list as B, then according to Equation 2: 
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𝐵 = 𝐴𝑈𝐶208
𝑛𝛾,208,177𝑚𝐿𝑢∗𝜖208 𝑒𝑥𝑝(𝜆177𝑚𝐿𝑢 ∗ 𝑃𝑎𝑠𝑠𝑒𝑑𝑇𝑖𝑚𝑒)         (6) 
Rearranging (6) we get:  
𝐴𝑈𝐶208
𝜖208
= 𝐵 𝑛𝛾,208,177𝑚𝐿𝑢𝑒𝑥𝑝(−𝜆177𝑚𝐿𝑢 ∗ 𝑃𝑎𝑠𝑠𝑒𝑑𝑇𝑖𝑚𝑒)         (7) 
From (5) we see that: 
𝐴𝑈𝐶208
𝜖208
= �𝐴177𝑚𝐿𝑢(𝑀𝑒𝑎𝑠𝐷𝑎𝑡𝑒) ∗ 𝑛𝛾,208,177𝑚𝐿𝑢 + 𝐴177𝐿𝑢(𝑀𝑒𝑎𝑠𝐷𝑎𝑡𝑒) ∗ 𝑛𝛾,208,177𝐿𝑢�      (8) 
This gives: 
𝐵 𝑛𝛾,208,177𝑚𝐿𝑢𝑒𝑥𝑝(−𝜆177𝑚𝐿𝑢 ∗ 𝑃𝑎𝑠𝑠𝑒𝑑𝑇𝑖𝑚𝑒) = �𝐴177𝑚𝐿𝑢(𝑀𝑒𝑎𝑠𝐷𝑎𝑡𝑒) ∗ 𝑛𝛾,208,177𝑚𝐿𝑢 + 𝐴177𝐿𝑢(𝑀𝑒𝑎𝑠𝐷𝑎𝑡𝑒) ∗ 𝑛𝛾,208,177𝐿𝑢� (9) 
Solving for 𝐴177𝐿𝑢(𝑀𝑒𝑎𝑠𝐷𝑎𝑡𝑒) this gives 
𝐴177𝐿𝑢(𝑀𝑒𝑎𝑠𝐷𝑎𝑡𝑒) =             (10) 
= 1
𝑛𝛾,208,177𝐿𝑢 �𝐵 𝑛𝛾,208,177𝑚𝐿𝑢𝑒𝑥𝑝(−𝜆177𝑚𝐿𝑢 ∗ 𝑃𝑎𝑠𝑠𝑒𝑑𝑇𝑖𝑚𝑒) − 𝐴177𝑚𝐿𝑢(𝑀𝑒𝑎𝑠𝐷𝑎𝑡𝑒) ∗ 𝑛𝛾,208,177𝑚𝐿𝑢� = 𝑛𝛾,208,177𝑚𝐿𝑢
𝑛𝛾,208,177𝐿𝑢 �𝐵 𝑒𝑥𝑝(−𝜆177𝑚𝐿𝑢 ∗ 𝑃𝑎𝑠𝑠𝑒𝑑𝑇𝑖𝑚𝑒) − 𝐴177𝑚𝐿𝑢(𝑀𝑒𝑎𝑠𝐷𝑎𝑡𝑒)� 
In this equation we can use the value 𝐴177𝑚𝐿𝑢(𝑅𝑒𝑓𝐷𝑎𝑡𝑒)𝑓𝑖𝑛𝑎𝑙  to determine 𝐴177𝑚𝐿𝑢(𝑀𝑒𝑎𝑠𝐷𝑎𝑡𝑒). However, we must calculate it to the MeasDate. 
𝐴177𝐿𝑢(𝑀𝑒𝑎𝑠𝐷𝑎𝑡𝑒) = = 𝑛𝛾,208,177𝑚𝐿𝑢
𝑛𝛾,208,177𝐿𝑢 �𝐵 𝑒𝑥𝑝(−𝜆177𝑚𝐿𝑢 ∗ 𝑃𝑎𝑠𝑠𝑒𝑑𝑇𝑖𝑚𝑒) − 𝐴177𝑚𝐿𝑢(𝑅𝑒𝑓𝐷𝑎𝑡𝑒)𝑓𝑖𝑛𝑎𝑙  𝑒𝑥𝑝(−𝜆177𝑚𝐿𝑢 ∗ 𝑃𝑎𝑠𝑠𝑒𝑑𝑇𝑖𝑚𝑒)� = 𝑛𝛾,208,177𝑚𝐿𝑢
𝑛𝛾,208,177𝐿𝑢 𝑒𝑥𝑝(−𝜆177𝑚𝐿𝑢 ∗ 𝑃𝑎𝑠𝑠𝑒𝑑𝑇𝑖𝑚𝑒)�𝐵 − 𝐴177𝑚𝐿𝑢(𝑅𝑒𝑓𝐷𝑎𝑡𝑒)𝑓𝑖𝑛𝑎𝑙   �       (11) 
And then we can calculate the activity of 177Lu at the Reference Date: 
𝐴177𝐿𝑢(𝑅𝑒𝑓𝐷𝑎𝑡𝑒)             (12) 
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= 𝑛𝛾,208,177𝑚𝐿𝑢
𝑛𝛾,208,177𝐿𝑢 𝑒𝑥𝑝(−𝜆177𝑚𝐿𝑢 ∗ 𝑃𝑎𝑠𝑠𝑒𝑑𝑇𝑖𝑚𝑒)�𝐵 − 𝐴177𝑚𝐿𝑢(𝑅𝑒𝑓𝐷𝑎𝑡𝑒)𝑓𝑖𝑛𝑎𝑙   �𝑒𝑥𝑝(𝜆177𝐿𝑢 ∗ 𝑃𝑎𝑠𝑠𝑒𝑑𝑇𝑖𝑚𝑒)= = 𝑛𝛾,208,177𝑚𝐿𝑢
𝑛𝛾,208,177𝐿𝑢 𝑒𝑥𝑝�(𝜆177𝐿𝑢 − 𝜆177𝑚𝐿𝑢) ∗ 𝑃𝑎𝑠𝑠𝑒𝑑𝑇𝑖𝑚𝑒��𝐵 − 𝐴177𝑚𝐿𝑢(𝑅𝑒𝑓𝐷𝑎𝑡𝑒)𝑓𝑖𝑛𝑎𝑙   � 
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APPENDIX XI     SUMMARY ON IDB 177Lu SPECIFICATION SHEETS 
IDB Radiopharmacy bv 
 1 2 3 4 5 
Lot number 12062012A 04062012A 30052012A 24042012B 17042012A 
Client code 24012-1 24012-1 24012-1 24012-1 24012-1 
Destination LU Hospital, Sw 
Required Activity 
(GBq) 18.5 9.3 18.5 9.3 9.3 
Required Calibration 
Date 
14.06.2012 (12:00 
C.E.T) 
07.06.2012 (12:00 
C.E.T) 
31.05.2012 (12:00 
C.E.T) 
26.04.2012 (12:00 
C.E.T) 
19.04.2012 (12:00 
C.E.T) 
Required Volume (mL) 0.7 0.4 0.7 0.4 0.4 
Reference Date 
12.06.2012 (19:08 
C.E.T) 
04.06.2012 (17:00 
C.E.T) 
30.05.2012 (12:19 
C.E.T) 
24.04.2012 (12:46 
C.E.T) 
17.04.2012 (16:21 
C.E.T) 
Lu-177 activity on 
reference date (GBq) 23.7 13.6 20.7 15.8 16 
Chemical form LuCl3 Lutetium Trichloride 
Solvent 0.05 M HCl Ph Eur. In WFI 
pH Value 1.4 1.5 1.3 1.5 1.3 
Expiration date 
26.06.2012 (19:08 
C.E.T) 
18.06.2012 (17:00 
C.E.T) 
13.06.2012 (12:19 
C.E.T) 
08.05.2012 (12:46 
C.E.T) 
01.05.2012 (16:21 
C.E.T) 
Lu mass (µg) 31.2 17.7 23.5 17.5 17 
Total Volume (mL) 0.7 0.4 0.7 0.4 0.4 
Volumetric Activity 
(GBq/mL) 33.6 38.9 29.5 45.1 45.5 
Specific Activity 
(GBq/mg) 762 770 880 903 938 
Lu-177m impurity 
(act.Lu-177m over Lu-
177) <0.05% 
Other radionuclidic 
impurities <0.01% 
Date: 12.06.2012 04.06.2012 30.05.2012 24.04.2012 17.04.2012 
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APPENDIX XII  SCHEDULE ON PATIENT MEASUREMENTS 
   
MONTHS AND WEEKS 
   
April May June July August  September 
Initials PATIENT M 14 15 16 17 18 19 20 21 22 22 23 24 25 26 27 28 29 30 31 31 32 33 34 35 36 37 38 
 
39 
 
AA 
PATIENT 1 
1       X                                                 
  
2                           X                             
3                                                         
TA 
PATIENT 2 
1     X                                               
  
2     X   
3                             X                           
CK 
PATIENT 3 
1               X                                   
  
2   X   
3                                               X         
MC 
PATIENT 4 
1                     X                                   
  
2   X                           
3                                                         
UH 
PATIENT 5 
1                       X                                 
  
2                               X                         
3                                           X           X 
SG 
PATIENT 6 
1                         X                               
  2                                       X                 
  3                                             X           
IN 
PATIENT 7 
1                         X                               
  
2                                       X                 
3                                                         
X    measurement performed 
X   planned measurement for the week no. 
1   measurement done 
2 measurement no. example 2 to be performed 
3 last measurement not performed 
 
